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Since the 1600s, public-private partnerships (P3s) have been a means of uniting the 
greatest strengths of the public and private sectors to create unique collaborations that share 
risk and reduce cost to produce public and semi-public goods. Despite P3s being used for 
centuries, they have only been integrated in the American health system and research 
activities since the 1990s, with very little research conducted to understand their strengths, 
weaknesses, and appropriateness in health and science. This is particularly true in burgeoning 
areas of scientific research such as neuroscience, where application of P3s is almost 
nonexistent. 
This dissertation investigates factors leading to successes and failures in existing P3s in 
neuroscience and examines how lessons learned might be used to construct public policy that, 
where appropriate, facilitates and supports P3s that move neuroscience forward. Exploratory 
methods are used, including 30 online questionnaires and 12 key informant interviews (KIIs) 
collected from six key stakeholder groups. 
The questionnaires revealed eight factors that either facilitate or hinder P3 creation 
and sustainability. KIIs revealed another five subfactors. All 42 participants discussed their 
perspectives on definitions of success and failure of P3s, resulting in a variety of definitions 
that often consolidated around stakeholder groupings. Results also exposed a number of 
anticipated factors that were either previously misunderstood or not as important to P3 
creation and sustainability in neuroscience as they are in other areas of focus.  
iv 
Findings suggest P3s could play an important role in advancing neuroscience research 
and work but much more is needed than federal and state-level policy recommendations for 
the uptake of P3s in science. Major barriers to neuroscience P3s exist within U.S. 
organizational culture and a guiding model for how to partner is lacking. Thus, the plan for 
change explains how modified public policy, a new P3 model, and an effective communication 
strategy may improve the pursuit of P3s in neuroscience. The plan for change proposes 1) 
federal and state policy changes to incentivize neuroscience-based P3s, 2) the creation of a 
new science-based P3 model, and 3) a communication strategy to improve public and private 
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CHAPTER 1: INTRODUCTION 
 
Background 
Economic growth and science-based developments in the United States have been 
greatly influenced by societal breakthroughs and the infrastructure of academic institutions 
since the 1600s.1 This is when the first public-private partnerships (P3s), toll bridges for 
transporting livestock and wildlife in Massachusetts, were documented in the United States. 
However, since that time, defining P3s and when they are best utilized has been difficult 
given the fluidity of definitions based on specific infrastructure goals and approaches.2 
Yet it is broadly agreed that P3s are contractual agreements between one or more 
government (public) agencies and one or more private sector or nonprofit partners, the goal 
of which is traditionally the delivery of public services or procurement of public or quasi-
public goods. Public services or goods can include anything from sanitation services to 
education to transportation.3 P3s are primarily developed to optimize management, 
innovation, and expertise within the private sector in conjunction with the regulatory 
knowledge and ability to protect the public interest of the public sector. 
P3s in transportation have been shown to not only increase operational expertise but 
to also mitigate risks associated with innovation, including financial investment.4,5 The result 
has been collaborations by stakeholders, which are individuals or organizations with interest 
or participation the outcome, with complementary skills and resources that can accelerate 
the development and delivery of products that neither the private nor public sectors can do 
independently.6 Thus, P3s have grown significantly in number and diversity across the globe, 
with up to 60% of public infrastructure being privately owned since the 1700s.7  
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The 1800s saw vast developments by autonomous investors (often wealthy families) 
that are thought of today as private equity or family offices. It also gave birth to the 
professional scientist, who was usually funded independently or by wealthy families to carry 
out specific work.8 There were few laws or regulations governing scientific discovery or the 
practice of medicine at that time.9  
In contrast, the 1900s produced a significantly more robust public sector that saw 
taxation for government public spending grow from approximately 6% to 34% of gross national 
product between 1900 and 1950.10 This included an expanded role for state and federal 
governments, regulatory bodies, and universities, solidifying them as key infrastructures of 
research funding and scientific work.11,12 
In tandem with the growth in government was the growth in academic institutions. 
Through the late 1800s, there were fewer than 1,000 colleges in the United States, and just 
over 150,000 students enrolled.13,14 By the conclusion of World War II, secondary education in 
the United States was seen as an instrument of national development. Between 1950 and 
1970, the number of universities more than doubled,15 and by 1999, approximately 6,500 U.S. 
postsecondary institutions awarded more than a million bachelor’s degrees.16,17 
With this growth in education came expansion into every facet of scientific research 
and specialization. As the demand for sugar, drugs, steel, and rubber skyrocketed in the 
1900s, so too did the demand for trained chemists and physicists. University laboratories grew 
to meet the demand for researchers. Or, as Goldin and Katz framed it, “With greater demand 
for trained scientists, universities expanded their offerings. With new research findings, the 
classical scientific disciplines became increasingly fragmented, resulting in greater 
specialization.”18(p. 39) This fragmentation also increased the number of specialties. 
What this means for public policy in the 2000s is an expansion of both the depth and 
breadth of responsibilities for the American government and public, as most university 
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research is conducted in the publicly funded academy. Individual researchers, entrepreneurs, 
and organizations can no longer work in silos or do everything alone. Academic institutions 
and private sector companies alike need partners, which are defined as those who engage in a 
formal agreement to share work and/or profits, within and outside of government to move 
ideas forward as well as secure funding and regulatory approval throughout the various phases 
of research and development (R&D). 
Public-Private Partnerships in Health 
When looking to other sectors that have successfully tackled large-scale issues and 
met public policy challenges similar to what science and medicine are currently facing, an 
appreciation for P3s is growing. From the initiation of research to the dissemination of that 
evidence, a co-dependence is increasingly happening between the public and private sectors. 
For example, the World Health Organization (WHO) stated in 2017 that governments could no 
longer be the only responsible agent in building sustainable societies.19 According to the WHO, 
corporate actors and the private sector are crucial in attaining public, sustainable 
development goals. 
Yet despite variations of P3s being used for centuries, only since the 1990s has there 
been a significant uptake of P3s in American health care and research.20,21 Before 1990, 
American-based academic journals published virtually nothing on U.S. P3s in health. But in 
the last 30 years, P3s have solidified a place throughout the American health ecosystem, 
predominantly in infrastructure projects (e.g., hospital construction) or vertical health 
initiatives (e.g., disease-specific drug development). By 2010, the United States was signing 
almost $4 billion a year in international health P3 contracts.22 Two driving forces of domestic 
and international growth in P3s since the late 1990s have been the Bill and Melinda Gates 
Foundation and the Rockefeller Foundation (founded in 2001 and 1913, respectively).23 The 
main foci of their collective P3 health initiatives have been on HIV/AIDS, tuberculosis, and 
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malaria in low-to-middle-income countries as a means of U.S. diplomacy and security and on 
multilateral collaborations for individual drug and vaccine development.24 
Although U.S. governmental agencies are no strangers to partnerships in health, there 
is still a noted disconnect between early-stage research and public impact,25,26 a problem in 
both the health and public policy arenas. Furthermore, as taxation and government 
procurement of research grows at a slower pace than during the last several decades, health 
funding and research gaps will persist.27 
P3s are an especially promising model for financing health-related R&D in emerging 
disciplines. Partnerships among state and/or federal government agencies, the private sector, 
academia, and financiers in the United States potentially stand to make research, 
development, and delivery of health care products and services more feasible.28 Yet a current 
gap in the literature exists regarding this potential in developing scientific fields, including 
how P3s might improve public policymaking that accompanies scientific breakthroughs.29 
Public-Private Partnerships in Neuroscience 
The human brain is believed to be the last frontier for medical research.30 This 
complex organ defines the individual’s self and controls everything from physical and mental 
development to complex decision-making to aging. Thus, the field of neuroscience is 
paramount to the broader context of human health and to an unlimited number of public 
policy arenas.  
Despite President George H. W. Bush proclaiming the 1990s the “Decade of the Brain,” 
research over the past 30 years is only beginning to reveal how the human brain works.31 
Consequently, advances in neuroscience research can, and certainly will, affect millions of 
Americans and billions of people around the world in areas such as childhood development, 
mental illness, and degeneration associated with aging. This means trillions of dollars in 
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medical care and R&D will be impacted by neuroscientific breakthroughs and by public policy 
decisions that influence neuroscientific research.32–34 
As science continues to march forward in ways that demand aggressive, yet ethical, 
approaches to learning about, diagnosing, and treating issues of the brain and central nervous 
system (CNS), the cost of R&D for a new drug (including cost of failure) now exceeds $2.5 
billion.35 So despite trillions of dollars in potential earnings from people worldwide who would 
benefit from advances in basic neuroscience, the R&D costs of drug development are proving 
too high even for pharmaceutical companies.36 This has led many risk-taking entities (e.g., 
pharmaceutical companies) to scale back, funding only products that can potentially reach 
“blockbuster” status.37 The result is foundational work being left by the wayside.  
Given that the private sector accounts for 80% to 90% of pharmaceutical products, 
abandoning upstream, basic research creates a growing gap that the public sector has been 
unable to fill, such as identifying the underlying mechanisms and pathways of brain 
development and degeneration.38 Add in shifting government regulations that guide the 
funding, development, and use of brain-based innovations, as well as the current lack of 
scientific proofs or standardized testing, and research discovery and clinical translational 
efforts have proven near impossible for investigators working in neuroscience.39,40 What this 
means is that the potential reward is no longer worth the effort. 
In the past 30 years, P3s in health have flourished while brain research has become a 
growing field and national priority. And yet, P3s in neuroscience are lacking. At present, only 
a few large P3s in neuroscience are being undertaken in North America—three of note in the 
United States and one in Canada.  
To spur across-the-board brain research, the National Institutes of Health (NIH) and 
the White House jointly launched the nationwide Brain Research through Advancing Innovative 
Neurotechnologies (BRAIN) Initiative in 2013, with the goal of integrating neuroscientific 
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discoveries across fields via P3s.41 The number of BRAIN Initiative partnerships to date has 
remained limited to a few specific areas of neuroscientific research, but those concentrated 
efforts have produced a number of publications. However, due to an unfixed budget and 
administration transitions, there has been marginal output from this initiative and little is 
known about successes or failures of the strategic P3 structure.41,42  
On the other hand, Brain Canada, the nationwide neuroscience-based P3 in Canada, 
has served globally as a model for companies and institutions looking to explore neuroscience 
P3s.43 One reason it has served as a model is that the P3s’ federal funding and structure 
support both policy-directed research and scientists’ autonomy to explore areas of interest. 
Unfortunately, Canada’s single-payer health system inhibits a one-to-one comparison for 
American institutions and agencies, as contractual and funding differences are great. Thus, 
the successes and failures of the national P3 can only provide loose guidelines for how a 
similar organization might partner in the United States.  
In a more singular-focused neuroscience-based P3, the National Institute of 
Neurological Disorders and Stroke (NINDS) and the U.S. Department of Defense (DOD) recently 
partnered with the University of California-San Francisco, a philanthropic organization, and 
Abbott Laboratories to launch Tracking Research and Clinical Knowledge in Traumatic Brain 
Injury (TRACK-TBI).44 The study’s principal goals are to improve traumatic brain injury (TBI) 
classification, treatments, and cost assessments. With more than 20 academic publications 
and multiple Food and Drug Administration (FDA) clinical trials in operation in its 6-year 
history, the TRACK-TBI P3 has been deemed an early success. 
In the field of degeneration, the flagship P3 in Alzheimer’s disease (AD), the 
Alzheimer’s Disease Neuroimaging initiative (ADNI), has demonstrated that hallmarks of 
disease exist decades before the onset of symptoms.45 Sadly, although the results of 
longitudinal studies have led to meaningful publications, clinical trials to develop biomarkers 
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have been limited to date. Additionally, despite more than 100 publications from the P3 
member organizations, funding is currently benchmarked to end in early 2021. 
Current trends, along with competing interests and limited resources, are not new to 
scientific research. Yet successful partnership models in other sectors indicate that it is time 
to establish health-related public policy that better supports emerging neuroscientific 
research. Particularly, public policy needs to incentivize, facilitate, and support meaningful 
advancement in neuroscience. 
Importance and Rationale  
Only with knowledge gained from neuroscience research can questions concerning the 
relationships between the brain, mind, body, environment, and disease be answered. But 
continued scarcity in government funding and recent decreasing return on investment (ROI) 
for neuroscientific research in the market creates difficulty and delays for researchers and 
scientists. Additionally, in the coming years, scientific innovations and advancements, along 
with an aging population, will increase demand for health services at an overall greater cost. 
Universities and public sector organizations will be forced to depend on more external 
financing, grants, and government regulatory bodies so investigators can conduct scientific 
and medical research. 
Private sector entities are not immune to the challenges faced by the public sector. 
Private entities must also work within government regulations and be accountable to 
agencies, while also worrying about increasing their ROI. As a result, more and more private 
sector companies are merging or acquiring neuroscience-based research instead of investing 
in their own R&D as they did in the past.46,47 Further, as there are more scientists, more data, 
and more complex scientific problems to solve, there is reason to believe more collaboration 
will result.48 This trend of uniting worlds additionally increases the private sector influence on 
health policy and health decision-making. 
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Therefore, the broad-ranging policy implications of neuroscience necessitate a deeper 
and richer understanding and scrutiny of the potential benefits and pitfalls of P3s as a model 
for collaboration. Furthermore, the influences public policy can have on initiating and 
maintaining partnerships are significant and must be better understood. With millions dying 
from brain diseases and lacking sufficient resources within any single sector or industry, there 
is no better time to assess P3s as a model and seek direction on crafting better policies that 
facilitate and support novel neuroscience research than now. To achieve this, there must be 
some guidelines on what P3s do that can enable researchers to gain valuable insights through 
shared resources and collaborative knowledge that advance the field.  
To date, the literature suggests that key components of a P3, both in and out of health 
care, are as follows:  
• Sharing risk and costs of groundbreaking research49 
• Bringing disparate sector expertise together50 
• Increasing diversity of thought 
• Accelerating the rate of R&D 
• Accelerating the uptake of research and products into the marketplace 
• Sharing goals and mission to foster collaboration and create new sectors51 
• Supporting open innovation and precompetitive research 
• Developing collective goals and contractual terms  
Thus, the purpose of this investigation is to understand the current landscape of P3s in 
neuroscience and to gain insight into factors that influence successes and failures of existing 
P3s. In addition, this investigation seeks to determine what factors shared by successful P3s 
can be appropriately integrated into the contextual landscape of neuroscience as best 
practices. Lastly, this investigation will share gained insights and recommendations from key 
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stakeholders to help public policymakers craft policy that moves the field of neuroscience 
forward by investing in P3s. 
Research Question and Aims 
This study employs three aims to answer the following research question: What 
Factors Influence Success in Public-Private Partnerships? Lessons for Neuroscience Policy. 
• Aim 1: Investigate factors that lead to successes and failures of existing P3s in 
neuroscience to understand the combination(s) of organizations and agencies that 
exist in the United States.  
• Aim 2: Identify factors within existing P3s that can contribute to successful 
research and scientific advancements in the field of neuroscience. 
• Aim 3: Propose federal and state-level recommendations to assist policymakers in 
constructing public policy that incentivizes and supports P3s that advance the field 




CHAPTER 2: LITERATURE REVIEW 
 
Partnerships exist to bring together a complementary set of skills and resources, with 
the goal of improving output, accelerating transformation, and lowering costs for a shared 
mission. As new fields of science emerge and established fields evolve, leveraging diverse 
expertise to advance knowledge often means embracing new models for collaboration. For 
the field of neuroscience in particular, successful partnerships will need to yield higher 
research productivity in areas ranging from brain development to disease states to drug 
discovery that can be disseminated to improve population health. 
Therefore, it is important to understand the past and current role that P3s play in 
neuroscience and how existing P3 practices can be used to improve future partnership 
creation and sustainability. While the principal goal of this work is to understand how public 
policy can facilitate and support scientific P3s in neuroscience, informing policymakers and 
crafting public policy cannot be done without an assessment of existing partnerships. A 
systematic literature review was conducted to understand the current state of P3s related to 
neuroscience. The findings uncovered the common themes and grounded examples of P3s 
relevant to brain-based research and work. 
Methods 
The following definitions were used for each of the key terms of interest: 
• Neuroscience: any science that studies the structure or function of the brain and 
nervous system.  
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• Public Policy: a system of laws, regulatory measures, courses of action, and 
funding priorities concerning a given topic. In this case, public policy refers to how 
government creates policies that affect the whole population.52  
• Public-Private Partnership (P3): a contract between a private party and a 
government or public entity for providing a public asset or service in which the 
private party bears significant risk and management responsibility, and 
remuneration is linked to performance.53 
Table 1 highlights the concepts and key words that were used as search terms for 
three databases: PubMed, Web of Science, and PsycINFO. (For additional key words and 
search terms, see Appendix 1.) 
TABLE 1: Key Words and Search Terminology for Analyses 
Concept Key Word(s) and Search Terminology 
Neuroscience “neurosciences” (MeSH term) OR “cognitive 
research” OR “brain research” OR “brain health” 
OR “neurobiology” OR “neurochemistry” OR “brain 
injury” OR “central nervous system (CNS)” 
AND 
Public Policy “public policy” (MeSH term) OR “policy” (MeSH 
term) OR “policy making” OR “legislation” 
AND 
Public-Private Partnerships “public-private sector partnership” (MeSH term) 
OR “public private partnership” OR “PPP” OR “P3” 
OR “partnerships” OR “collaborations” 
Abbreviation: MeSH, Medical Subject Heading. 
Inclusion and Exclusion Criteria 
Only articles published in English between January 1, 1985 and August 31, 2019 were 
included in this review. The date range was chosen based on the number of neuroscientific 
advances that occurred during this period as well as the growth of P3s beginning in the early 
1990s. It was also based on the vast federal-level policy changes that occurred in the U.S. 
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health sector during this period. Both qualitative and quantitative studies were allowed. 
Meta-analysis and systematic reviews were also included. Books and book chapters were 
permitted in the search but yielded minimal results. Due to the vastly diverse set of 
governmental regulations, academic rigor, and scientific standards, P3s that did not include 
at least one American-based or Canadian-based partner were excluded. 
After duplicates were removed, abstracts of each study were reviewed by the primary 
investigator to extract the journal name, publication year, article title, authors, and both 
dependent and independent variables. Based on a review of each abstract, some articles were 
excluded and a more thorough, full-text read of the remaining articles was conducted. A 
PRISMA diagram (Appendix 2) was constructed to visually demonstrate the flow of article 
selection through the different phases of the systematic review.54 
Findings 
The primary research results identified 65 unique articles (see Appendix 2) on either 
the structure and/or assessments of P3s in health, public policy, and neuroscience-based P3s. 
Title and abstract review excluded 26 articles. Consequently, 39 articles were examined in a 
full-text review, 21 of which were eliminated based on exclusion criteria. In addition, five 
articles were excluded because the proposed partnerships did not fit the P3 definition for this 
review, two articles were excluded because the neurologic application or focus was outside 
the scope of this review, and two articles were excluded because they were an out-of-date 
phase of a later study that has been included.  
References of the remaining nine articles were searched for potential additional 
relevant studies, but none were identified. Eight of the nine articles were qualitative in 
nature: three were background materials on existing P3s, two were expert opinions, two were 
narrative literature reviews, and one was a policy brief; there was one empirical study. Eight 
of the nine articles addressed key characteristics of the P3 being evaluated and provided 
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longitudinal information about the organizations involved in the partnership. The sole purpose 
of one article was to explain how public policy impacted a P3 in the field of neuroscience. 
After the nine articles were individually analyzed and synthesized, some common 
themes began to appear. First, the structure and leadership of each P3 was discussed at 
length. Second, the scope and mission of the organizations involved in each P3 were very 
narrow in nature. Third, only one article explored the role of public policy. Thus, the 
systematic literature review was divided into three areas of focus: 1) strengths of governance 
in existing P3s, 2) shared disease-specific goals that drive most American-based partnerships, 
and 3) the gap that exists in public policy implications of P3s.  
Public-Private Partnership Strength in Governance  
Affiliating various stakeholders in a rapidly changing environment requires leaders who 
understand which skills and resources are best deployed, where, and when, according to one 
P3 funded by the DOD. Yet it also requires extensive up-front groundwork in which those 
leaders lay out the goals, expectations, and outcomes that are equally owned and executed 
by all stakeholders involved. The Traumatic Brain Injury Endpoints Development (TED) 
Initiative asserts that the leadership role taken by study investigators within a P3 has the 
overall biggest impact on both establishing the partnership and maintaining the 
collaboration.55 TED researchers also maintain that its greatest achievements are due to the 
creation of data sets that “harmonize study measures” across all major investigations, thanks 
to its leadership establishing shared standards before TED’s founding.  
This claim is proving to be true in basic science and clinical research. For example, 
Jones-Davis and Buckholtz56 found that the ADNI’s success in progressing not only basic 
research but also translational and clinical research is because of its early-established data 
collection, measurement, and reporting specifications across sites: “A good deal of ADNI's 
success can be attributed to the strategic establishment of research standards among the 
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partnership's stakeholders.”(p. 860) Jones-Davis and Buckholtz also assert that having both 
academic and industry scientists included in the development of common protocols made 
collective buy-in fairly seamless.  
Brain Canada reported a similar theme about governance through its motto “One Brain 
One Community.” According to Jabalpurwala,43 the only way Brain Canada has been able to 
invest more than $180 million to support 168 projects and more than 750 neuroscience 
researchers across Canada since 1998 is through a shared and standardized understanding of 
what is expected across disciplines and facilities. However, in this unique national example, 
the significant financial investment of the Canadian government is matched by the 
intellectual investment of the public universities. Not only are academics able to explore 
areas of personal expertise and interest, but policy-backed priorities can also be financially 
incentivized for those interested. The author is quick to note that only with strong 
government and/or private partner funds and strong research commitments is a national P3 
like Brain Canada able to build the leadership community and governance necessary to set 
and sustain those shared metrics and deliverables. 
Disease-Specific Trends in Neuroscience Public-Private Partnerships 
Unlike Canada’s broad commitment to neuroscience P3s, the United States has built 
its brain-based P3s around specific diseases, almost exclusively within the aging population, 
including AD and related dementias such as Parkinson’s disease (PD). Despite a broad range of 
funders and partners, Liu et al.45(p. 860) note that the ADNI has a narrow overarching aim to 
“accelerate the understanding and validation of biomarkers” in AD. While the implications are 
to improve the speed and success rate of clinical trials for therapeutics, biomarker acquisition 
and analysis is a precise focus that involves its own Private Partner Scientific Board for 
oversight and guidance of the P3.  
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The same has shown true for PD, where organizations investigating disease 
mechanisms have tight genetic or environmental foci. In this space, Shihabuddin et al.57 
believe that P3s appear to have distinct value for supporting trial design optimization, 
increasing drug development, and obtaining regulatory approval because of deepening 
understanding of PD mechanisms. The authors point out that in each of these distinct areas 
within PD research, the sharing of expertise, industry knowledge, and precompetitive 
partnering enables success. 
Crous-Bou et al.58 also found that narrow cohort-focused P3s have been useful for 
establishing a framework for identifying and selecting individuals to participate in clinical 
trials. Specifically, they concluded that studies focused on preclinical stages of AD were best 
suited to utilize P3s for subject identification due to having access to the population of 
interest. However, it appears that while the partners share a disease of interest, patient 
cohorts of concentration, and specific goals, the definitions used for P3s might be very loosely 
based on partnership scenarios. 
To focus on individual diseases and injuries that include a larger cross-section of AD, 
Feldman et al.59 suggested a collective AD “roadmap” centered around P3s in the 
precompetitive space. They also called for the use of P3s to incentivize more rapid data 
sharing and the ability to draw larger investments into the broader AD world. Unfortunately, 
like the existing P3s in the neuroscientific space, the authors contend that without outside 
influence, biomarker research and clinical trial design will likely remain the two primary 
areas of focus for years to come. 
One neuroscientific area of study outside degeneration that has benefitted from P3s is 
TBI. In the DOD TRACK-TBI study, investigators have been conducting research in emergency 
departments around the United States to gather information on the incidence of, and factors 
associated with, TBI and post-traumatic stress in both civilian and military populations. 
16 
Haarbauer-Krupa et al.60 contend that the recent success of screening in these populations is 
directly because the TRACK-TBI P3 allowed for “standardized data collection and review” and 
patient identification across P3 sites. Given the confined focus of the TRACK-TBI P3 and its 
broad reach across the United States, the authors predict the offshoot of TED will produce a 
noteworthy number of publications in the coming years.  
Public Policy and Public-Private Partnerships 
Although P3s in American health care have existed for nearly 30 years, there is almost 
no literature assessing their potential role in the future of neuroscience. Because P3s are new 
in neuroscientific research, little attention has been paid to their broader ability to inform 
public policy and, in turn, how policy can facilitate and/or support P3s. In 2012, Fins et al.61 
attempted to delineate the major policy threats to deep brain stimulation and devices related 
to neurosurgery. While the authors had a very narrow scope of interest that is difficult to 
associate with other areas of brain research, the policy implications related to struggles with 
obtaining intellectual property and market approval can be applied to many fields of 
scientific discovery. The authors detailed how partnering private funding and expertise with 
federally funded research can prove useful to other neuroscience researchers going forward if 
ownership rights and credit are granted.  
Overall, the major takeaway from the only publication on public policy and 
neuroscience P3s was that crafting public policy that facilitates and supports P3s in 
neuroscience cannot be limited to legislative language and appropriations. It must also 
include regulatory agency action, up-front contractual boundaries, and, in some situations, 
engagement before and during clinical trials. Furthermore, there is an extensive amount of 




Over the last several decades, there has been a growing global presence of P3s along 
with literature investigating their successes and failures. However, the results of this 
systematic review suggest that there is currently a very limited understanding of how to 
address, regulate, or fund advancements in neuroscience using P3s. This emerges in part 
because the literature does not have a single definition of a P3 and there is no commonly 
used existing model for developing or assessing science-based P3s.62 In most instances, 
authors highlight “what could be” if partnerships were to achieve success. Unfortunately, 
there is a lack of empirical evidence because so few relevant P3s exist. 
Additionally, because neuroscience is in its infancy, the literature is far from complete 
to assist in optimizing P3 formation, governance, and maintenance for informing policy. 
Instead, this literature review highlighted the scarcity of research seeking to understand what 
kinds of partnerships facilitate new research, products, and best practices, particularly in 
neuroscience. Overwhelmingly, studies have focused on specific neuroscientific and CNS 
advancements that have not yet entered or completed U.S. FDA clinical trials. Alternatively, 
the focus was on P3s that are unique in their composition or goals in ways that were so 
specific, they are not appropriate to extrapolate. 
What consistently arose in the literature review, however, was the need to determine 
P3-wide goals and measurement standards early. Furthermore, in the process of reducing 
research silos, both community-level and corporate partners need equal input and support. 
There was also regular reinforcement for pursuing narrowly focused research topics such as 
AD to TBI that allow for more targeted goals. Finally, current P3 participants appeared to 
agree that P3s need to be enacted earlier and accelerated faster in the scientific discovery 
process, both in funding and collaborative work.  
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A review of the literature to date highlights just how significant the gaps are in 
understanding the role that P3s play in the field of neuroscience. Furthermore, there are 
overlapping themes around the governance of successful P3s in other health sectors and 
existing P3s in the neuroscience space that are ripe for exploration. The literature review 
helped shape the context, validate the overlapping themes, and inform questions for surveys 
and key informant interviews about the current state and potential of P3s. Thus, it is possible 
that with a more concentrated assessment of P3s in the field of neuroscience, along with 
policy recommendations based on those findings, P3s could become a substantial model in 
neuroscientific research.  
Limitations  
This literature review had several limitations. First, it was conducted by a single 
reviewer. Second, the search terms used were very broad, as a search of narrow terminology 
found no applicable studies. Third, the generalizability of the findings is limited by restricting 
the literature review to U.S. and Canadian studies.   
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CHAPTER 3: METHODOLOGY  
 
Research Aims 
This study has the following research aims: 
• Aim 1: Investigate factors that lead to successes and failures of existing P3s in 
neuroscience to understand the combination(s) of organizations and agencies that 
exist in the United States.  
• Aim 2: Identify factors within existing P3s that can contribute to successful 
research and scientific advancements in the field of neuroscience. 
• Aim 3: Propose federal and state-level recommendations to assist policymakers in 
constructing public policy that incentivizes and supports P3s that advance the field 
of neuroscience. 
Study Overview 
This study utilizes a qualitative approach to understand the successes and failures of 
P3s in the field of neuroscience as well as potential influences on developing public policy for 
neuroscience. Specifically, the qualitative methods generated detailed descriptions of how 
experiences, perceptions, context, and key informant information provide credible insights 
into the current state of the field and culture.  
For Aim 1, an open-ended questionnaire was disseminated to 30 randomly selected 
subject matter experts (SMEs) in the fields of neuroscience, partnerships, and/or public 
policy. To provide a deeper and more detailed day-to-day exploration of how P3s can be 
utilized in the field of neuroscience, Aim 2 entailed key informant interviews (KIIs) that were 
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conducted with 12 SMEs randomly selected from the same, but nonoverlapping, pool of 
potential participants as the questionnaire. The triangulated results from Aims 1 and 2 were 
used to guide Aim 3, a Plan for Change that includes an action-based set of recommendations 
for policymakers on how to improve public policy that facilitates P3s and supports 
neuroscientific research.  
Conceptual Framework 
The Centers for Disease Control and Prevention (CDC) has created the Strategic 
Partnering Framework (Figure 1) as a process guide for forming and maintaining strategic 
partnerships in health.63 The CDC approach is comprehensive, beginning with organizational 
self-assessment before a partnership is established and advancing through evaluations and 
reassessments after a partnership has been created. Thus, it has garnered global traction in 
recent years, with use cases ranging from local governments to national governments 
throughout Europe and North America.64,65  
In both Wales and Nova Scotia, for example, the Strategic Partnering Framework was 
used as a guide for building partnerships between the government and academic institutions. 
In the United States, the framework has also been utilized for partnering with both large-
scale and narrowly focused projects before and during collaboration. At the City University of 
New York, the framework was used to facilitate an HIV primary and secondary prevention 
model to be used in the United States.66  
Because of the holistic approach of the Strategic Partnering Framework and the 
continual feedback loops for monitoring and evaluation, as well as the vast uptake of the 
model globally, it was chosen as the conceptual framework for this investigation. Not only is 
the framework readily accessible and recognized in global public health, but its ability to be 
applied at any level of partnership and by any participating stakeholder were strengths 
guiding questionnaires and KIIs created for this study. 
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FIGURE 1: Strategic Partnering Conceptual Framework 
 
Source: Rogers M, Kent L, Lang J. Strategic Partnering: A Guide to the Conceptual Framework 
How to Use the Strategic Partnering Framework. Atlanta, GA: Centers for Disease Control and 
Prevention. 
https://www.cdc.gov/dhdsp/programs/spha/roadmap/docs/Strategic%20Partnering%20Conce
ptual%20Framework_ac.pdf. Accessed October 6, 2019.  
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The left side of the CDC framework depicts the organization in which the participant 
has worked previously or currently that has been a part of a P3; the right side depicts the 
partnering organization(s). The center column defines the steps generally taken in the health 
sector and common questions to consider before entering a partnership. Using the CDC 
framework, the study questionnaire and interview were framed around the process of P3 
reflection, partnering, assessments, maintenance, and evaluation, in that order.  
Study Design 
Aim 1 
Investigate factors that lead to successes and failures of existing P3s in neuroscience to 
understand the combination(s) of organizations and agencies that exist in the United States.  
Building on the systematic literature review and conceptual framework, Aim 1 used an 
online open-ended 15-item questionnaire (Appendix 3) sent via email, which was designed to 
learn more about the role of P3s in neuroscience. The questionnaire structure was crafted to 
explore how each stakeholder and their respective organizations have experienced and view 
P3s, as well as the best practices, lessons learned, and opportunities for P3s in neuroscience. 
To accomplish this, the questionnaire was divided into four thematic sections, each 
containing either three or four questions. The four thematic sections were sequential in 
nature and included: 1) high-level personal and organizational background, 2) knowledge and 
experience in P3s, 3) structure and governance of P3s, and 4) data and outcomes of P3s. The 
questionnaire was reviewed by a SME in neuroscience and in P3s for verification. The 
questionnaire was also reviewed by a social research expert at the University of North 
Carolina’s Odum Institute. 
An open-ended questionnaire was chosen to garner richer insights from participants. 
For example, each stakeholder was likely to have a different definition or example of a 
“success” or a “failure” as it pertains to partnerships and their experiences. However, until 
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there is a greater understanding of what various stakeholders want, need, contribute, and 
expect from P3s, as well as previous experiences and opinions, we cannot know how to 
properly incentivize, facilitate, or evaluate P3s. Where appropriate, results of the Aim 1 
questionnaire were utilized to adjust a KII script focused on adding context and application to 
the themes and taxonomies gained from the questionnaire. The University of North Carolina 
at Chapel Hill institutional review board (IRB) approved Aim 1 in late November 2019. 
Data Collection 
The goal of Aim 1 was to obtain 30 completed questionnaires from SMEs in the fields of 
neuroscience and P3s who could provide a broad picture of the current state of these fields.67 
To accomplish this, five SMEs were selected from a master list created by the principal 
investigator (see Appendix 4 for a list of eligible participants) of U.S.-based experts and 
practitioners from each of six stakeholder groups within or around the field of neuroscience, 
including 1) academic researchers, 2) medical clinicians, 3) financial investors, 4) government 
agency representatives, 5) advocacy or lay group representatives, or 6) policymakers (see 
Table 2). The diverse expertise and experience of these six stakeholder groups was intended 
to provide a robust picture about the creation and sustainability of P3s in the real world. 
These six stakeholder groups were believed to be homogenous enough to see thematic 
overlaps, or recurring and unifying concepts.67,68 However, the stakeholder categories and 
sample size were not intended to find convergence on themes between groups. 
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TABLE 2: Subject Matter Expert Stakeholder Groups 
Stakeholder 
Group 




These individuals spend 80% or more of their compensated time with an 
affiliated academic institution conducting academic-based research, 
teaching, and/or administration. This can also include scientific journal 
editors, department heads, or new faculty on tenure track. University 
settings, and those who work in and around them, bring vital 




At minimum, these individuals spend 50% or more of their compensated 
time providing MD-level clinical care or working with patients in a 
medical setting. It is in these settings that unique data can be collected 
and research can be disseminated, a key aspect of health-related 
partnerships. Given that up to 50% of compensated time can be in 
nonclinical settings, these individuals can also be entrepreneurs, 




Individuals who work within private and public organizations, 
universities, or government agencies (of any size) that are responsible 
for supplying money, grants, or funding bring a unique perspective to 
what it takes to run a partnership. These individuals also look at 
investments into health, science, and returns on their (or their 
organization’s) investments in ways that lend insight into how deals are 




Government agencies at the state and federal levels play an integral role 
in crafting public policy, from disseminating research funding to providing 
regulatory oversight to setting scientific priorities. Individuals who work 
for government agencies provide a one-of-a-kind perspective on how 
scientific research is approved by and supported in the United States. 
Advocacy or  
Lay Group 
Representatives 
Those who become advocates and aim to grow public support and 
awareness around health-related issues are often vocal leaders for 
scientific work that is not their own but rather for a particular cause, 
patient population, or policy. These individuals also often serve as a 
bridge between the lay community (general public), scientists, and 
policymakers. Their consensus-building skillsets are a unique aspect of 
health partnerships. These are most often nonprofits, but they cannot 
be labeled as such given the variation of nonprofit organizations and 
the blurring of lines between public and private nonprofit funding.69 
Policymakers 
These individuals work in and around government (whether elected, 
appointed, or hired) at the local, state, or federal level influencing 
decisions elected officials make. Thus, policymakers include elected 
officials themselves, their staff, their advisors, those lobbying them, or 
individuals who disseminate relevant information such as think tanks 
and former officials. This perspective is vital for understanding how 
public policy can influence P3s and be influenced by P3s. 
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The master list of potential participants was generated from a combination of subject-
related conference attendees, neuroscience-based conference and lobbying activities, 
meetings, current U.S.-based neuroscience P3s, volunteers from networking events attended 
by the primary investigator, and guidance from dissertation committee members who work in 
the neuroscience field. A list of at least 20 potential participants within each of the six 
stakeholder groups was generated. To avoid selection bias and give each stakeholder within 
stakeholder groups an equal chance of participation, five individuals were selected at random 
from a Microsoft Excel workbook as primary participants from each stakeholder group, and 
another five as alternative participants. That Microsoft Excel workbook contained each 
potential participant’s name, email contact, and their professional role. Participants’ 
background and experiences did need not to be in a neuroscience-based P3s, but they had to 
be able to provide information about the dynamics of P3s and how they impacted each 
stakeholder’s specific area of expertise in neuroscientific research.  
SMEs were emailed questionnaires via SurveyLegend using a secure login. If the SME 
declined to complete the questionnaire after 1 week, a backup SME within the same 
stakeholder group was contacted using the same protocol described above.  
Data Analysis 
Questionnaires were submitted via an online portal at the SurveyLegend site. Once 
participant survey completion was confirmed, SurveyLegend exported a de-identified copy of 
the survey into both a password-protected Microsoft Excel spreadsheet and a Google 
Document to a secure external hard drive. The primary investigator was then notified that a 
questionnaire had been submitted and was available for download.  
The study approach used grounded theory, with categories and codes developed 
throughout the entire analysis of the questionnaires.67 After five questionnaires were 
submitted, the principal investigator reviewed them and created a codebook using two 
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approaches: open coding and axial coding. Open coding was used as the initial stage of 
questionnaire review.70 Each answer was reviewed line by line to build categories and themes 
around recurring or unifying concepts or statements. The codebook included the code itself, a 
description and definition based on the data, and an example of the code for reference. 
Subsequently, axial coding was employed to construct linkages across questionnaires.71 By 
constantly comparing identified themes, trends began to appear, and theories about what 
behaviors and influences determine successes and failures of P3s began to be explored. For 
instances where a participant answer crossed multiple themes, the investigator revisited the 
question being asked, as well as reread the sentences around the potential themes to gain 
added context. In some instances, particularly for answers defining success and failure, 
answers crossed several factors and were included in the codebook more than once.  
To improve reliability in the coding of open-ended questions, a second reviewer 
independently coded the first five questionnaires using the structured codebook.72 Where 
divergence in coding arose in Microsoft Excel workbooks, the reviewers coordinated verbally, 
reached a consensus on the hierarchical code, and revised the codebook accordingly.73 
Subsequently, every five completed questionnaires were reviewed independently by the 
principal investigator and second coder. This iterative process was used to increase interrater 
reliability.74  
Aim 2 
Identify factors within existing P3s that can contribute to successful research and scientific 
advancements in the field of neuroscience. 
Aim 2 involved KIIs with two interviewees from each of the six SME stakeholder groups 
(see Table 2 and Appendix 4). Twenty-four individuals who were not selected for Aim 1 were 
randomly selected for Aim 2 KIIs: 12 as primary KIIs and 12 as backup participants should the 
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primary key informant be unavailable for an interview. Each key informant was asked a total 
of 12 questions (Appendix 5) that lasted a maximum of 60 minutes.  
Data Collection 
The principal investigator randomly sampled SMEs within each stakeholder group who 
were expected to provide deeper contextual clues and expectations for constructing 
successful partnerships.75 They were specifically asked (see Appendix 5) to think more 
intentionally about the role of public policy and how policymakers might facilitate or hinder 
and support or undermine the growth of neuroscience and brain-based research. The KII script 
was based on the CDC’s conceptual framework (Figure 1) but revised to reflect results and 
findings from Aim 1 at its completion.  
Before the KIIs were conducted, the proposed KII questions and structure were 
reviewed by a SME in neuroscience P3s and a social research expert at the University of North 
Carolina’s Odum Institute. Once the questionnaire was finalized, the principal investigator 
scheduled in-person KIIs when available. Phone interviews were conducted when in-person 
interviews were not possible. With verbal informed consent secured from each participant, 
the investigator audio recorded each KII on a MacBook Pro computer for transcription. 
Detailed field notes were also taken by the investigator for later contextual clues and 
comparison to the audio recording transcripts.  
Data Analysis 
All recordings were transcribed by Rev to verify against the investigator’s notes and 
check the quality of the transcription.76 The principal investigator reviewed each transcript as 
it was completed and created the initial codebook when the first KII was finalized. As with 
Aim 1, both open coding and axial coding were employed, which began with a line-by-line 
review to build categories and themes around the recurring or unifying concepts or 
statements. Additionally, where participant answers appeared to cross themes, the question 
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and surrounding sentences were revisited for added context, and the answer was noted in the 
codebook where appropriate. Again, the KIIs were reviewed by two coders, and differences 
were resolved by consensus before continuing to the next transcript.  
Aim 3 
Propose federal and state-level recommendations to assist policymakers in constructing 
public policy that incentivizes and supports P3s that advance the field of neuroscience.  
Implementing research-based knowledge into everyday action is fraught with barriers 
and complexity. Thus, using the collective knowledge gained from questionnaires and KIIs to 
craft recommendations to assist policymakers in facilitating partnerships in science 
necessitated the use of an implementation framework. Further, the selected framework must 
be both broad enough to apply to a range of neuroscientific endeavors and specific enough to 
identify barriers and facilitators for translating ideas to action.77  
For that reason, the Knowledge to Action Framework (Figure 2) was chosen for this 
investigation.78 The Knowledge to Action Framework synthesizes and contextualizes 
information gathered prior to implementation and attempts to help create an evidence-based 
tailored set of recommendations for how to achieve desired outcomes.79,80  
This framework helped guide how data from Aims 1 and 2 were used to inform public 
policymakers—specifically, how to integrate the knowledge gained to craft recommendations 
that address key public policy issues such as implementation, legislation, appropriations, and 
agency action and oversight. Furthermore, the framework includes monitoring and evaluation 
periods during which the actual outcomes are observed, and future actions can be adapted, 









CHAPTER 4: RESULTS 
 
Aim 1  
Investigate factors that lead to successes and failures of existing P3s in neuroscience to 
understand the combination(s) of organizations and agencies that exist in the United States.  
Of the 30 initial potential participants contacted, 23 (76.7%) completed the survey; 
the seven non-responding participants were replaced with a randomly selected alternative 
from their stakeholder group. Of those seven, six completed all 15 questions; the one who did 
not was replaced with an alternative in the stakeholder group, resulting in a total of 30 
completed questionnaires.  
Eight factors were identified that participants reported may facilitate or hinder the 
creation and sustainability of P3s. Participants also discussed their perspectives on the 
definitions of success and failure of P3s. These are presented in the sections below.  
Emergent Factors 
Table 3 outlines factors that participants reported may facilitate or hinder the 
creation and sustainability of P3s. 
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TABLE 3: Emergent Factors From Subject Matter Expert Questionnaires 
Factors Takeaways 
Alignment  
Mission, expectations, objectives, and deadlines should be coordinated 
enough that each partner has clarity, understanding, responsibility,  
and accountability for a part of the bigger purpose. One overarching 
common goal or mission needs to unite various stakeholders. Alignment is 
most difficult when the return on investment is not consistent between 
partners or the partners are working toward different goals. 
Goals 
Well-defined goals are needed before the start (contractual signing, data 
collection, or research) of a P3. Goals need to be clearly stated so that 
funding can be appropriately distributed. However, goals need to be 
revisited and reevaluated on a regular basis, as do metrics for qualitative 
and quantitative outcomes and benchmarks.  
Trade-Offs 
To create anything new, there is inherently a trade-off of time, focus, 
funding, energy, and other resources. However, each partner brings 
different skills and resources to the table. Thus, complementary (not 
competitive) assets help mitigate trade-offs. Time is the single biggest 
trade-off for individuals and organizations in a partnership. Employing the 
Build versus Buy Decision Matrix helps make this easier for each partner.  
Communication 
Clear internal and external communication is critical to ensure all staff, 
partners, stakeholders, and the broader public have enough information to 
make informed decisions. Further, transparency is essential to build trust. 
There should be consistent interaction via check-ins with specific, 
objective reporting metrics. 
Structured 
Flexibility 
While many pre-P3 organizational assessments and planning elements need 
to be set before embarking on a partnership, the partnering entities must be 
flexible enough to incorporate unanticipated shocks to the system (funding, 
regulatory, political), real-time data related to the P3, and/or shifts in 
partners (which could include adding new, or dropping current, partners).  
Measurements 
Data across all partners’ systems (e.g., patient data, financials, staff 
retention, time management) should be defined and measured 
consistently. Internal or external data that are not collected, analyzed, 
and presented in the same way are misleading in their findings. Mission-
critical data include data from the partners, as well as the impact on 
patients, community, and target populations.  
Policy 
Policy timelines are often at odds with research timelines. To influence 
policy, P3s need a coordinated plan and communication system to share 
appropriate information. Appropriations often shift with “hot” topics of 
societal priority. However, the government has a unique ability to extend 
funding and share risk when policymakers are informed and/or interested 
in a specific body of work. The regulatory environment can be expensive 
and daunting, and regulations can be both helpful and harmful.  
Culture 
Culture reflects both individual and corporate personalities, values, and 
norms that must be compatible to build trust across partners. Incentives 
for each stakeholder are paramount to keeping engagement and 
momentum. This includes individual cooperation and trust to defer when 
appropriate (data collections, standards, and protocol). 
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Factor 1: Alignment 
Alignment, defined as “being in agreement” or “on the same page,” was identified as 
a theme by 22 stakeholders (73.3%). In most instances, the theme was used to describe how 
personal and organizational interests, priorities, and values should be similar enough that the 
work ethic, respective contributions, and direction of the project(s) move in parallel. When 
referencing what should be “in alignment,” examples include “mission,” “expectations,” 
“objectives,” and “deadlines.” 
“The greatest challenge in formulating a P3 is alignment of priorities and 
goals.” 
“Alignment of priorities for two organizations is the biggest hurdle.”  
“As a company, we look for a few key things in our synergies. The first is the 
alignment of vision. If you’re in agreement about a higher purpose, there’s 
greater commitment to improving specific outcomes.” 
Interestingly, the concept of being in alignment was frequently used as a caution, 
suggesting that “misalignment” can be a significant risk to P3s viability. In fact, four 
respondents directly linked misalignment to the ultimate demise of a partnership.  
“If interests fail to align, the partnership dissolves. Period.” 
“In the context of my current work, failure happens when entities within the 
partnership are not fully aligned on expectations, objectives, deadlines, and 
any other aspects of contractual engagement.” 
Several participants noted that timelines and budgets operate more efficiently when 
stakeholders are in alignment. When less time is spent clarifying expectations, resolving 
conflicts, and resetting direction or next steps, more research can be completed faster. To 
accomplish this, multiple respondents highlighted the need to align incentives, which keep 
people working toward rewards that complete the intended agreed-upon goals.  
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“The reward structure needs to be aligned with outcomes. People pay 
attention to what they think they'll be judged on. Celebrate successes, no 
matter how small they may seem.” 
“We always try to get incentives aligned. That way we are setting the 
relationship up as a true partnership and not a vendor/client relationship.”  
Factor 2: Goals 
Several questions were posed to SMEs about setting P3 goals and how those might 
differ from other partnerships or single-entity priorities. Goals were defined as desired results 
participants want to achieve.81 While every participant spoke about goal setting, there was 
great variation in when goals should be set, how they should be determined, and by whom. 
For example, 11 respondents (36.7%) explicitly stated that goals should be set before any 
contractual agreement is signed by P3 participants.  
“Partnership goals should be laid out in advance to ensure expectations are 
met before, during and after implementation.” 
“If the end-goals are not fully aligned and the two groups have different 
expectations, you can waste a lot of time trying to find common ground. The 
problem being solved and its goals needs to be clearly defined up front.”  
“I think it's very useful when public organizations set goals for what they want 
to achieve, and then hold workshops where they invite potential partners to 
attend and then make proposals on how they could participate. FDA Sentinel's 
5-year plan that came out in Dec 2018 is an example of an organization being 
clear in what it wanted to achieve and that led to many private organizations 
then reach[ing] out to form partnerships.” 
In contrast, other respondents thought that goals should be set after a P3 has been 
established so that the participating entities get to know one another by pursuing a common 
mission. Their rationale partners need to be connected to truly understand each other’s 
wants and needs.  
“The most important goal is the first one: define the mission. Everything else 
will follow.” 
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“I have had the fortune of being part of a highly successful P3, and they are 
rooted in relationship building. By this I mean a deep understanding of both 
shared and individual organization goals from the outset. And building from 
there. For example, if one person wants a lot of publications and another 
wants to treat more patients, you need to know that before setting joint 
goals.” 
“Once a partnership is solidified, then leaders should set clear and defined 
mutual goals. When two partners have different long-term goals, it 
complicates short-term missions.”  
Eight participants (26.7%) suggested that goals can—and often should—be updated 
regularly by the P3 leadership, especially in response to new information becoming available.  
“Most partnerships last more than a couple of years, so I expect evidence to 
re-defined goals over time.” 
“Realistic and achievable goals have to be periodically updated.” 
There was great consensus among respondents on the need for “well-defined goals” 
using clear wording, precise metrics, benchmarking, and quantitative information that helps 
determine the “health of the P3.” It was also noted that goals need to be clearly stated so 
funding can be correctly appropriated and distributed. 
“Establishing clear goals and expectations for outcomes is key. Using SMART 
goals (specific, measurable, achievable, relevant, and time-bound) is how we 
approach goal setting.”82 
“Clear and consistent goals with outcomes that are easily understood as 
positive are crucial for public sector partners. Easy-to-measure deliverables 
without subjective measures of success are important for private sector 
partners.” 
 “Specific goals are essential for a sustained relationship.” 
Four respondents with backgrounds in government and financial investing remarked on 
the competing priorities of public and private entities in goal setting. Their statements 
revealed some of the inherent difficulties with bringing disparate wants together to achieve 
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common goals. Yet others noted that these differences can be beneficial for setting shared 
expectations. 
“The overwhelming public sector preference for transparency and 
accountability are understandably at odds with the goals of certain private 
sector entities. Particularly if for-profit sub-contractors are engaged.” 
“Again, everyone’s goals matter. Are you looking for stakeholder satisfaction 
or awareness campaign market reach? Or both?” 
“What makes the public organization so attractive to the private organization 
is that there is regulation that keeps private organizations from achieving 
goals without support from the public organization. So, in this context, I think 
regulatory forces are a positive influence on forming P3 partnerships and 
goals.”  
Factor 3: Trade-Offs 
Several respondents spoke at length about trade-offs that individuals and organizations 
must make to participate in a partnership. However, few participants used the phrase “trade-
off” itself, instead using “balance,” “sacrifice,” and “giving up” to describe what is forfeited 
to create or participate in a P3. Individual time was commonly cited to emphasize how 
creating a partnership can be draining on individuals. In particular, it was noted that time to 
focus on the P3 is limited by traditional roles and responsibilities that continue to exist for 
employees once a P3 is established. 
“TIME is probably the single biggest challenge. Finding the time away from 
other obligations to seek out partnerships.” 
“You're working with folks that are literally doing brain surgery. You're 
working with people that are extremely time constrained. I wish I had more 
time. So, it’s really about how do you manage time? How do you balance to 
get more out of your day for the group? 
“The trick with partnerships is to control the competing organizational needs. 
Every organization has its unique demands and processes. When working 
jointly, those competing internal needs need to be balanced with the new 
group needs.” 
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“[The] biggest hesitation is time... It’s easy to let yourself, or your 
organization, get spread too thin. And you can’t let primary work suffer at the 
hands of new projects.” 
Because each partner brings unique skill sets and resources, other partners that bring 
complementary assets can help lessen the burden of losing time, focus, funding, energy, and 
other resources to participating in the P3, according to respondents. 
“Complementary assets are the main reason to partner. But that can mean a 
lot of things, gaps. I mean, you do whatever it takes to fill those gaps if you’re 
on a mission.”  
One strategy posed by two respondents to help decide when to accept inconveniencies 
for benefits was to employ the Build versus Buy Decision Matrix.83 Although it was noted that 
the decision to partner is not identical to buying another company, it is analogous to going it 
alone (build) versus not (buy). Specifically, respondents drew parallels to the process of 
determining if in-house or outsourced solutions will be most beneficial to organizations in the 
short and long term.  
“I formalize the process: 1) Decide priority areas of focus in health. 2) Make 
the build/buy decisions.” 
“The first step is the choice of the design-build-operate models, which need to 
be agreed upon, including sharing of risks that may be not be obvious at the 
outset.”  
Factor 4: Communication 
Half of the respondents commented on the importance of communication, and several 
others noted the importance of “check-ins” and “touch-points.” The observations about 
communication varied between operational and programmatic on the need for communication 
(internal and external) to increase stakeholder and community buy-in. For most, the need for 
communication is a product of the day-to-day planning and operations of the P3, ensuring 
that partners are fully aware of key metrics and benchmarked progress to make informed 
decisions.  
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“At the core of a partnership failure is when timely, open, and candid 
communication among key stakeholders stops.” 
“For a partnership to work, you need clear communication about goals, roles, 
and division of labor. And clear communication when those things are not 
going to plan.”  
“There should be effective communication at all times and make sure that all 
expectations are clear.”  
Additionally, some respondents described what happens when there is not consistent, 
objective communication.  
“Without a doubt, my experience with partnership failure has been directly 
related to poor communication.”  
“Communication is critical along the way. Once you build the roadmap for the 
vision, you have to set up touch-points along the way to determine if you are 
on track and hold folks accountable. If you don’t, you’ll find out too late.” 
For those whose communication focused on trust-building and stakeholder buy-in, the 
word “transparency” was used regularly. To accomplish this, both internal and, more 
importantly, external messaging must “speak to the audience” and partners must be wary of 
using each stakeholder’s jargon and language.  
“Information, metrics, and outcome must be developed and communicated 
through collaterals, manuscripts, reports, etc. depending on the audience 
asking for them or needing them. For example, the public will most likely 
want user-friendly communication and PR materials that is succinct and to the 
point. The scientific community will want detail[ed] reports, data analysis, 
etc., conference presentations, etc.” 
“Interaction with the public is critical. You need their feedback, and you need 
their buy-in. That’s why so many good public health campaigns utilize social 
media and even celebrities.” 
“No communication usually will result in a failed effort because no one will 
trust you. It’s no different than any other relationship.”  
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Factor 5: Structured Flexibility 
 Respondents from all six stakeholder groups consistently mentioned the need for 
flexibility, which included “being open to change,” “allowing compromise,” “adjusting,” and 
“anticipating unknowns,” Flexibility was consistently framed in a constructive manner, often 
directly tied to goal setting and structured operations when beginning a P3 and making 
decisions as partnerships mature. Five participants described that unintended consequences 
based on P3 actions are inevitable, and thus, anticipation of new information should somehow 
be “baked in” to the monitoring and evaluation plans. 
“A well-defined goal as well as secondary outcome measures that are well 
defined are crucial at the outset. But flexibility to incorporate unanticipated 
variables or outcomes into the final work-product [is] essential to keep a 
partnership viable and successful.” 
“You have to constantly re-evaluate and adjust the goals for the partnership, 
both strategic and tactical, from the mission statement to intermediate, 
perhaps even project-specific aims.”  
“You need a flexible framework and mindset.” 
“Organizations that focus on lean workstreams that are modular can often 
course correct much faster than organizations or partnerships that always 
have the same target goal. They need the flexibility.” 
“For a partnership to work, leadership must be open and flexible to challenges 
that are presented. They have to balance the negotiables and non-
negotiables.” 
Flexibility was also viewed as a means of justifying a P3 model. For example, 
individuals in the private sector tended to believe that they are more flexible or “nimble” 
than their government or academic counterparts. Several respondents gave examples of how 
flexibility can be perceived as a hinderance or as an asset to potential partners.  
“In general, the federal (public) agencies do not allow for significant 
innovation, whereas foundations and [the] private [sector] tend to be a bit 
more flexible.” 
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“People in the sciences, neuroscience in particular, are hesitant to partner 
with government because it has so many guardrails it can’t be nimble. But you 
also can’t get a product, device, or therapy to market without them. So, best 
to engage them early.” 
“Public sector partners need to be assertive and [make] sure that results can 
be measured and demonstrated within important cycles of the public 
appropriations calendars. Private sector partners need to make sure that they 
have the flexibility to complete meaningful work on a realistic schedule and 
are not being forced to manipulate results based on political timetables.” 
Factor 6: Measurements  
Respondents primarily thought of measures in two ways: 1) descriptive and diagnostic 
measures within the P3, and 2) impact on the community or patient group of interest. For the 
former, quantitative and qualitative measures assess the value of the information. These 
measures help identify what benchmarks and targets are or are not being met and why. These 
measures also inform the partners about the “value-add” of the other partners.  
“When monitoring and evaluation measures are set in place, the understanding 
is that through assessment, insight can be gained. Ultimately, the concept of 
‘value-add’ is the expectation I would have for all partners involved, 
essentially evaluating if the relationship is still satisfactory to move forward.”  
“Data measurements highly [depend] on the context and situation, but they 
have to be consistent across sites. What metrics can answer whether or not 
you're achieving the objectives/and ultimately the goal(s), and are they being 
collected and presented in a manner representative of where they come 
from?” 
“Easy-to-measure deliverables without subjective measures of success are 
important for private sector partners.”  
Two participants claimed measurements are necessary to improve the likelihood that 
financial resources are not going to waste on unsuccessful projects. 
“Financially, there always needs to be clear outcomes that are measurable for 
funding to be appropriated correctly and not to be wasted.”  
An additional use of measurement pertains to internal P3 activity, data collection, and 
deliverables. Six respondents explained why data measurements (collection, analysis, and 
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reporting) should be determined at the outset of the partnership, and why a SME should be in 
control of the planning and execution.  
“Evaluation tools should be set by those with expertise in the area. However, 
all partners should sign off on agreed measurements and outcomes.” 
“Data governance plans are critical, and should be managed only by the data 
and analytics experts who can be accessed via a small committee, for 
example.”  
“The party performing the collection, measurement, or assessment should be 
responsible for proposing protocol and methodology. The expectation is that 
the other partner(s) should agree or suggest amendments, with final approval 
from the one doing the work.” 
“The approach to neuro data should be clearly worked out before beginning 
any project—with clear objects/hypotheses and well-defined methods to get to 
the outcome. The measurement will be important for the study—both for 
monitoring progress and safety.”  
Only two participants argued that data planning, management, and reporting protocols 
should involve input from all stakeholders. They advocate for addressing data management 
after forming the partnership.  
“If the data collection/aggregation is the reason for the P3 existence, then the 
protocol’s skeleton shall be established and agreed upon in principle by all 
partners.” 
Six respondents explained that measurement can be used to assess impact on patients, 
community, and target populations outside of P3 operations; they saw benefits from 
discussing how outreach efforts to the community and predictions can make the biggest 
impressions on specific populations or disease states. 
“For us, success is ultimately measured in the level of service provided and 
the cost-savings to people.” 
“Information and numbers of patients helped, resources made available, [and] 
how useful the stakeholders found the program is what matters most.”  
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“If it is a public-private partnership ... then it's imperative that the results 
from the research be about the community. What is best for the COMMUNITY?” 
Factor 7: Policy  
Although the word “policy” was used by 17 respondents, only nine used it in reference 
to policymaking as intended for rulemaking and regulation (as opposed to current political 
parties, specific elected officials, and party affiliations). Notably, policy was addressed by all 
five respondents from the “policymaker” stakeholder group and four respondents from the 
“financial investor” stakeholder group. However, how they applied the word policy and 
discussed the role of policymaking was vastly different. For instance, financial investors spoke 
frequently about “risk,” suggesting that the unpredictability of policy changes and the 
number of regulations in the health care space were daunting, hindering, and to be avoided 
when possible. It was frequently thought of as an “external force” that could disrupt existing 
P3s.  
“Policy-based financial and regulatory forces are seen as stifling to private 
organizations. Government bureaucracies have proven to be slow and 
frustrating.”  
“It is very difficult to innovate in government. People don't want to change 
because they don't have to, and that is dangerous. It’s also why the 
government almost always loses its strongest, highly skilled employees for the 
private sector.” 
“The biggest influences on the development of a private-public partnership 
can be divided government and predetermined mindsets of political decision 
makers towards the services being provided and policies that support them.” 
“Partnering is always tricky with the government because you need to 
maintain an acute awareness of the administration’s goals, i.e., not partnering 
with a group that does not mesh with the policymakers, so as to stay in good 
graces.” 
In contrast, policymakers often noted the importance of policymaking as a tool for 
“appropriations” and “funding.” They were also consistent in explaining that it was their 
responsibility to share risk with the academic and private sectors when appropriate, often 
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based on governmental needs. However, they claimed this required a deep level of 
interaction and understanding, influencing policymakers to frequently reference 
“communication” as a trust-building activity.  
“The best partnerships are usually government facilitated, since we have the 
most restrictions. We can lay out the most that we are able to do given our 
constraints and private organizations can meet us where we are.” 
“However, those of us at agencies lend creditably due to influence at the 
policy level and have access to funds that the private sector does not (e.g., 
through our federal sources) which are often strengthened by a strong 
partnership.”  
“Government entities can assume risk the private entities can’t often manage 
from an insurance perspective.” 
“Government-facilitated partnerships are essential in reducing the financial 
burden to the governments if appropriate solutions could be devised to reduce 
the cost. A good example is Medicare/Medicaid, where CMS spends in excess of 
a trillion dollars every year. Partnerships that will reduce the cost of drugs to 
CMS can readily save billions and make many drugs more accessible.”  
Three comments on policy centered around the desire to influence policymaking for 
regulatory agency standards. The primary means of doing so were through communication 
strategies and partnering early to build trust. It was also discussed as a strategy for dealing 
with the shifts in “hot topics” that often alter appropriations to issues that are important to 
the social or political discourse.  
“The biggest challenge [in] dealing with the very long timeframes of P3s is 
uncertainty of funding. Knowing the right policy people in our field of interest 
can help with this if we play our cards right.” 
“If a government organization that is responsible for patient privacy decides 
to use our software for research projects of its own (even if this is not a 
financially lucrative partnership for us), the goodwill and credibility of the 
government agency can help build confidence for our product and solution.” 
“Policy affects us because we are working with appointed officials, resulting in 
frequent changes on who makes the decisions about our funding and our rules. 
This results in us needing to alter our pitch or even our project to satisfy a 
new audience.”  
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Factor 8: Culture 
Every respondent noted individuals’ personalities, egos, and ultimately, the 
organizational culture. These findings suggest that culture is as or more important than 
business strategy. They thought that individual personalities or corporate culture within the 
partnering entities can determine the sustainability of a P3. This was most frequently 
addressed through use of positively associated phrases such as “trustworthy,” “fit,” and 
“mission-driven.” 
 “The #1 priority should be focused on building the correct culture.” 
“Chemistry and cultural fit are what lead to success. We often consider the 
soft criteria as equally weighted with the standard checklists. Making sure 
everyone wins is critical.”  
“Ideal partners have mutual trust in each other’s expertise and have the 
humility to defer when appropriate because they are working towards the 
same mission.” 
Individual personalities and corporate culture were also referenced through the use of 
negatively associated phrases such as “want recognition” and “put themselves first.” This 
proved particularly true when non-academics referred to academic culture and 
nongovernmental participants described their view of government.  
“Loss of recognition for a successful outcome can turn a partner into a 
competitor.”  
“Some entities are interested only in their own agenda, which hampers a free 
flow of ideas.”  
“The silos that exist in federal government [are] very consequential of culture 
and tribalism. One group had a falling out with the other years ago, and 
therefore each will now go on duplicating processes, etc.” 
“The greatest challenge to overcome is a failure of ‘internal culture’ to 
embrace innovation/change.”  
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“Partnerships are like dating. Trustworthy behavior can be recognized early 
on, but bad actors, behavior, and greed can ruin a trusting relationship.”  
Several participants gave insights into the methods they believe are best suited to 
improve culture so partners, leadership, and staff are motivated to work toward a common 
goal. In all instances, the solution involved providing an incentive for making them feel like 
their work matters; this closely reflected the advice given for improving organizational 
alignment by providing rewards and incentives to get buy-in from staff. 
“Everyone wants to feel that they are doing something that matters. Keeping 
that in mind, no matter what we are doing or where we are doing it, has 
always been helpful to me. People and organizations start competing or 
become possessive when they feel irrelevant.” 
“Ultimately, one strong leader with either an altruistic agenda or an incentive 
good-for-all-partners model may bring the P3 to success.” 
“We always set up the incentives from the beginning. We have a plan around 
outcomes that we set and hold vendors accountable for those milestones. 
There are also penalties associated with not achieving the promised 
outcomes.” 
Key Findings  
Defining Success  
Definitions and examples of “success” in a P3 are very closely aligned with the overall 
identified factors (Table 4). For example, all six stakeholder groups mentioned “goals” and 
“alignment” as necessary for success, and five groups spoke to building “trust” and good 
“communication.” Four of the six stakeholder groups talked about impact and the need to 
measure and demonstrate impact to either internal or external stakeholders. Three of the 
groups also mentioned lack of “ego” as a necessity for success. Interestingly, respondents’ 
statements often reflected an ideal state that had not been personally experienced.  
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TABLE 4: Aim 1—Most Commonly Used Descriptors for “Success”  
in a P3 by Stakeholder Group 
Stakeholder 
Group 
Most Commonly Used Descriptors for “Success” in a P3 
Academic 
Researchers 
• Societal impact; value to citizens 
• Completing study, research, or other shared end-goals and 
objectives 
• Clear and well-defined output that benefits clinical care 
• Subjective and objective mutual benefit 
• Working toward shared goals 
Medical Clinicians 
• Building trust locally and in broader landscape 
• Information flowing freely between partnering organizations 
• To have an impact on the health care system 
• Patient impact; improve/make a measurable difference in patient 
experiences and outcomes (quality of life, interactions) 
• Financial benefit 
• Hitting targets  
Financial 
Investors 
• Meet objectives on time and on/under budget; realistic timelines 
• Everyone wins; a lot of small, sequential wins 
• Launch something (service/product/policy/care) that would not 
exist without the P3; sustainable products/projects 




• Real solutions to real problems; solving a problem 
• Clear goals; clear roles; structure; agreed-upon measurements 
• Working together; collaboration; healthy exchange of resources 
• Building awareness with no care to credit; not worried about 
brand; network and reach further as a group 
• Sustainability; long-term commitments; something that lasts  
Advocacy or Lay 
Group 
Representatives 
• Delivering impact to target population; real-world impact  
• Clear goal setting; meeting well-defined goals 
• Speaking the same language; on the same page for growth;  
cross-disciplinary work 
• Shared mission, vision, and passion; mutual growth; 
complementary skills that grow strengths and lessen weaknesses 
Policymakers 
• Complementing works—not competitive 
• When work can be done after the P3; each can do their own work, 
but the P3 enhances the long-term work of each  
• Clear, mutual goals; SWOT (strengths, weaknesses, opportunities, 
and threats analysis) and timelines are agreed upon 
• Regular, defined communication; trust; lack of communication  
• Governance structure that facilitates decision-making; governing 




When asked to provide examples and depictions of “failure” in a P3, respondents also 
proved to be closely aligned with the eight emergent factors (Table 5). Specifically, all six 
stakeholder groups noted lack of “alignment” and “communication” as a contributing factor 
to failures. Five groups (83.3%) blamed contrasting or dissimilar “cultures” for P3 failures. 
Four groups (66.7%) spoke about missed “goals” that may seem small in the bigger picture of 
the P3 but are, in fact, early signs of a larger P3 failure. In contrast to definitions of success, 
participant statements for failure reflected personal lessons learned and very direct 
experiences.  
Aim 2  
Identify factors within existing public-private partnerships that can contribute to successful 
research and scientific advancements in the field of neuroscience. 
Of the 12 potential key informants initially contacted, eight (66.7%) completed the 
interviews; the four non-responders were replaced with a randomly selected alternative in 
their stakeholder group. Of those four alternative participants, two completed interviews. 
The remaining two non-responders where replaced with other alternatives, resulting in 12 
completed interviews. 
The overarching eight factors identified in Aim 1 (Table 3) were consistently used 
within and between the KIIs.84 No new overarching factors were added, but a few meaningful 
insights were revealed by the experienced key informants who provided a richer explanation 
of behaviors and influences that impact P3s based on their closely working with, and 
participating in, P3s. Specifically, five additional subfactors were identified that gave insights 
and examples of P3 operational structure, coalition-building through communication, data 
and intellectual property considerations, and culture (Figure 3). Table 6 provides high-level 
takeaways of the subfactors. 
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TABLE 5: Aim 1—Most Commonly Used Descriptors for “Failure”  
in a P3 by Stakeholder Group 
Stakeholder Group Most Commonly Used Descriptors for “Failure” in a P3 
Academic 
Researchers 
• A loss of core values; deviation from mission 
• You do not fail, you learn 
• Not having the right partners at the table  
• One or more partners feeling like they did not benefit from joint 
work 
• Partners who jump ship before the work is done 
Medical Clinicians 
• Wasting time; not pivoting when you should and losing time 
• Finding out too late you are not in alignment; failure begins with 
a lack of vision and well-defined goals 
• Lack of funding due to poor planning 
• Lack of adoptability/implementation by the public 
• You cannot fail if you have resiliency to learn from mistakes 
Financial Investors 
• Partner “feet dragging” that leads to untenable timelines; team 
misalignment 
• Funding failures 
• Not listening to all voices (particularly the small ones) 
• Ambiguous goals; misaligned targets 
• Missed targets; falling short of desired outcomes 
• Loss of or no trust 




• Stated goals are not achieved; missing an objective goal or a 
timeline 
• No communication 
• Lack of teamwork; seeking individual credit or recognition; 
hoarding information 
• Unequal footing in P3 
• Competing priorities 
• Leave room for small failures up front 
Advocacy or  
Lay Group 
Representatives 
• Dishonesty; manipulation 
• Having resources and not using them; not executing on  
something viable 
• Not executing on time 
• Do not have a defined vision; misalignment; do not share goals 
• Communication is poor; bad mouthing  
• Unforeseen costs; budgets that are not doable 
Policymakers 
• Different long-term goals that harm short-term missions;  
conflict in outcomes; too little time was spent on SWOT 
• Coming in over budget; funding loss 
• Underdelivering; lack of follow through  
• Cultures that do not come together; relationships that do not mesh 
• Leadership that does not lay out a roadmap; lack of governance 




FIGURE 3: Emergent Subfactors 
 
 
TABLE 6: Emergent Subfactors From Key Informant Interviews 
Subfactors Takeaways 
Leadership  
The most important roles of leaders are to champion the collaboration 
internally and externally through a clear vision and mission, communicate 
regularly with all stakeholders, make decisions quickly, and provide cover for 
decisions that are made internally. Leadership is distinct from operations in 
most cases for high-functioning P3s.  
Management 
P3s are always an addition to employees’ workload, so managing day-to-day 
operations is a critical role that is often outside top leadership’s primary 
focus. Because deliverables and accountability for milestones are a primary 
necessity, a designated person in management is a P3 must-have. This role 
should also focus on communication coordination and organization of 
meetings to keep the stakeholders and staff on target.  
Intellectual 
Property 
Intellectual property, information ownership, and scholarship recognition are 
a fast-growing problem for partnerships. These issues must be addressed 
before the P3 begins, as conflicts during a partnership can greatly harm the 
P3. It is vital to think about “what” will be available to whom; “how” it can 
be used, shared, or sold; and “who” will receive the credit.  
Trust 
Trust of partners and trust from the broader community are necessary for 
implementation and uptake of P3 outcomes or results. Without internal trust, 
P3 operation problems arise quickly. Without external trust, results will not 
be believed and potential solutions will not make it to the communities who 
need them. This is inherently linked to communication and transparency.  
Ego 
More than organizational culture, because P3s usually involve a small core of 
leadership and staff, egos are the primary driver of conflict and failure to 
follow established protocols. The presence of egos was consistently framed in 
a negative sense conveying the unfavorable impact it has on the overall 












Emergent Subfactors: Key Findings 
Alignment Subfactor: Leadership 
All 12 key informants commented on the role that leadership plays in setting the 
“tone,” “example,” and “guardrails” for the rest of the staff and stakeholders. This was most 
frequently denoted by championing a clear vision and mission, communicating it regularly 
with all stakeholders, and removing barriers to employee responsibilities. 
“I expect leaders to have clarity of mission, honesty, clear chain of command, 
and regular communication.” 
“Simply put, I believe in the ‘benevolent dictator’ model. That being said, 
leadership is an essential component to frame the efforts and drive the 
process through a strategic vision.” 
“Firstly, leaders need to be present, attend meetings, and continuously assure 
participants that the partnership is a priority. It's common for this to fall off 
the list of an executive on a long list of competing priorities. Secondly, 
leaders need to continuously cast the vision for the partnership and ensure 
that they are supplying what the players in the partnership need, by breaking 
down barriers and supplying resources.” 
“Once a partnership is solidified, leaders should set clear and defined goals, 
and ensure communication and transparency are top priorities.” 
“Being able to have [an] ample runway to get it off the ground and knock 
down initial obstacles with leadership support can inspire the teams and bring 
resolution to early issues, which build a solid foundation.” 
In contrast, three respondents made clear that the role of leadership was to oversee 
the P3 but give the experts the day-to-day ability to do their jobs. The primary job of the 
leader(s) is to make decisions quickly based on the most relevant information.  
“I just need a leader who is able to remove blockers and make strategic 
decisions.”  
“Leaders need the ability to make decisions even when unpopular and the 
humility/bravery to listen to subordinates on the front line to inform decision-
making.” 
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“I think senior leadership should say what needs to get done and then stay out 
of the way and let the groups execute autonomously.” 
Alignment Subfactor: Management  
Separate from leadership, nine of the 12 key informants differentiated the need for, 
and role of, management. They expressed repeatedly that P3s do not often have dedicated 
personnel for project management, but that it is an important feature of any successful 
operation.  
“No one goes into a partnership with other things coming off their plate. But 
they can't do it all. So there absolutely has to be that operation-type program 
manager or something like that who keeps the ships moving.”  
The role of management was most often identified as the person(s) performing day-to-
day operations that “keep the trains running on time.” Three informants conveyed the need 
for a distinct role in the P3 that holds others accountable to protocols, deliverables, 
commitments, timelines, and regularly scheduled reporting and communicating. However, 
there was no preference as to whether this dedicated responsibility should be an internal or 
external hire.  
“Honestly, the most important role to me is a superb program manager that 
stays on top of milestones, organizes the meetings, and [coordinates] 
communications. Without this, you can have the best experts in the world and 
nothing will move forward.” 
“Excellent project management is essential. It seems so obvious, but it’s 
actually not a position that’s built into our partnership models.”  
“Someone must be dedicated to driving the process. There is often no clear 
responsible entity for managing and organizing the project. But someone has 
to break down goals into discrete pieces and call people out when red flags are 
raised. This either has to be bought and paid for via the grant or funding or 
provided by one of the entities.”  
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Trade-Off Subfactor: Intellectual Property 
Intellectual property, information ownership, and scholarship recognition are rapidly 
growing issues that P3s must address. With the evolution of data collection, management, and 
selling of information, participants noted an increasing need to build intellectual property 
rights and distribution contracts into the initial P3 contracts, as conflicts during a partnership 
can greatly harm the P3.  
“Twenty years ago, even ten, we didn’t talk about intellectual property and 
ownership as a part of the negotiation process. But today, data is currency.”  
“In 2019, proprietary/intellectual property need[s] to be discussed during 
SWOT. Not doing so at the beginning of the engagement would clearly derail a 
partnership.”85 
“Limitations on data sharing and use should be spelled out at the beginning 
and are often dictated by specific institutional policies. Intellectual property 
and scholarship roles/rules must be clearly delineated.” 
Key informants spoke to the difficulty in this, as it involves a lot of foresight into what 
information will be available, to whom, and how that information might be used, shared, or 
sold. Further, one’s rights to information has become a major driver of willingness to partner 
with others. 
“Who owns the project’s successes, who can talk about it, and whose real win 
is it anyway... for example. Organizations really struggle with this, because 
showcasing successes is how you a) get more work, b) keep doing the work 
you're doing, [and] c) [are] trusted to take on something like it in the future. 
Showcasing successes is critical to business development, for example.” 
“Ownership of data and rights matters. Open access information is key to 
moving forward in my research realm. If we can have a protected database 
with credit for data collection, thoughts, etc. … to keep people’s intellectual 
properties intact, that would be key reason to collaborate.” 
Several respondents described the process of handling ownership and intellectual 
property as a formal part of the contractual process. Two specifically cited the use of binding 
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legal contracts as a means of preventing future conflict and removing stress from the 
partners.  
“These issues are always challenging, especially among neuroscience-based 
P3s. Higher education institutions, health entities, and experts want to be 
associated with addressing critical health issues impacting the public. 
However, I have found that it is vital to raise and address such delicate and 
legal matters when P3s are being cultivated and developed. I find that MOUs 
and agreements help to address such matters, as well as contracts.” 
“Ideal partnerships shall operate in a precompetitive setting for 
information/data ownership and IP development potential with all players 
benefiting and ‘drinking from the same well.’ Regulatory documents, 
DUAs/MTAs/DSAs/etc. and even patient consent forms’ language shall be 
agreed upon prior to any information collection.” 
Communication Subfactor: Trust 
Key informants frequently used the word “trust,” which was applied both internally 
(within the P3 itself) and externally (those outside of the P3). Respondents believed that 
without internal trust, P3s can quickly dissolve. However, they also consistently conveyed 
that frequent and clear communication can be one of the greatest trust-building activities for 
stakeholders and partners (individuals and organizations) of the P3.  
“The essence of a partnership is trust. If you don't trust who you're working 
with or if you don't talk to the person on the other end of the project, then 
everything can fall apart. It’s the core of a partnership.” 
“Essentially, all stakeholders should have an opportunity to communicate and 
take part in the organization of the P3 so that transparency and trust are built 
in from the very beginning.” 
“When you are looking to sign a contract with another company, there has to 
be a level of trust. But establishing that early on is one of our biggest 
challenges we face.” 
Key informants also repeatedly noted that trust from the broader public/community is 
necessary for implementation and uptake of P3 outcomes, results, or products. Without 
external trust in the groups that the P3 is trying to engage, results may not be believed or 
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properly shared in the right manner; should this occur, potential solutions would not make it 
to the communities that need them. Key informants linked building trust externally to 
“communication” and “transparency.” 
“Government may be more legitimate to some stakeholders but is not trusted 
by some communities. So, we have to get out there and educate them on why 
we need all the partners to be effective.” 
“The partnership’s job is first and foremost accuracy in reporting and 
accountability. This is critical to maintaining the public trust.”  
“All you need is the perception of COI (conflict of interest) and you lose the 
trust of the nation.” 
“I think of success in terms of building trust, both in the local community and 
larger brain health landscape. These public-private partnerships allow for 
bringing people along if you know how to story tell. You’ve got to make the 
care that comes out of the partnership relevant to the person by walking them 
through personalized scenarios.”  
Culture Subfactor: Ego 
Seven key informants used the word “ego” to describe how corporate culture might 
influence a P3. When asked to explain the role of ego, they explained that in most P3s, a 
small core group of people are involved in decision-making, and the ego of one person can 
harm the culture of the entire partnership. One interview expounded on the failure of those 
with “large egos” to follow agreed-upon protocols and practices. All seven respondents who 
used the word ego framed it as negatively, including phrases such as “self-serving” and 
“sabotaging.” 
“The biggest risks for partnerships are in egos of their founders and 
participants. This may end up in sabotaging collaborations, not sharing 
data/resources, or even partnership dissolution with wasted resources, good 
will, and bruised organizational and personal egos.”  
“We have to make it a priority to set aside the need to get credit and boost 
the ego. Just do the work.” 
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“Because we work with a lot of small organizations, individual egos can really 
affect the outcomes of a partnership.” 
“Individual egos not being checked at the door. That is the number one thing I 
see causing partnerships to fail and organizations to crumble, particularly 
when working with academics and medical doctors.”  
While giving examples of when ego can harm a relationship, three of the respondents, 
all non-academic stakeholders, remarked on the academic culture as a primary source of ego.  
“Academic culture (heavy incentives for publications) means a lot of egos of 
researchers. Whilst academia and academics claim to promote and stimulate 
collaboration, in practice the individualized culture of their world means 
there is more competition.” 
“It's amazing how many researchers are out there who sabotage important 
agendas because of ego.” 
One respondent went so far as to describe a matrix he had personally created to 
understand and illustrate what incentives will drive a partner based on their ego’s willingness 
to work in collaboration.  
“Motivations are multiple, from necessity/insufficient resources (funding, 
data, ideas) to ego-boosting (participation in something bigger, more 
prominent, public, successful). I have developed and [am] happy to share an 
“EGO-MATRIX” that illustrates multiple participants’ incentives to 
collaborate.” 
Success and Failure: Key Findings 
Each participant was directly asked to describe what a successful P3 looked like from 
their perspective, as well as what a failure of a P3 looked like to them. Their definitions of 
success and failure are presented in Tables 7 and 8.  
 Defining Success  
Definitions and illustrations of success provided by key informants closely paralleled 
those provided by questionnaire respondents and the overall identified factors found in Aims 
1 and 2. For example, “communication” and “culture” were used by five of the six 
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stakeholder groups. When asked to provide examples of success, key informants in four of the 
groups mentioned lack of “ego” and “trust” as major factors for P3 success. Informants from 
three key stakeholder groups also spoke about the role of “leadership” and “management” in 
meeting “goals” and increasing P3 impact. As with Aim 1, when describing success, KII 
participant statements often reflected an ideal or aspirational state that had not been 
personally experienced. 
TABLE 7: Aim 2—Most Commonly Used Descriptors for “Success”  
in a P3 by Stakeholder Group 
Stakeholder Group Most Commonly Used Descriptors for “Success” in a P3 
Academic 
Researchers 
• Leave the world better off 
• Developing relationships and projects that go beyond the P3 
• All parties view joint work as advantageous 
Medical Clinicians 
• Open, unfettered communication 
• Sustainability of proposed or implemented change 
• Remain mission-driven 
Financial Investors 
• Reduce duplicative efforts 
• To “stir the pot” 
• Receiving press for a good outcome 




• Having boundaries; building a “coalition of the willing” 
• Trust 
• Builds legitimacy  
Advocacy or  
Lay Group 
Representatives 
• Getting something to happen or preventing something  
from happening 
• Iterative learning 
• Cultural fit and values 
• Deep understanding of the work 
Policymakers 
• The level of services provided and cost-savings to an agency  
(i.e., taxpayer) is high; advancing people’s outcomes 
• No need for taking credit  
• Having “skin in the game”; oversight 
 
Defining Failure 
As with success, key informant’s definitions and examples of failure consistently used 
words like “misalignment,” “communication,” and “culture” as reasons for failure. 
Informants from three of the stakeholder groups mentioned lack of well-defined goals or 
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different risk tolerance in trade-offs as reasons that P3s fail. Informants from two groups 
directly or indirectly pointed to failures in “leadership” and “management” as the core of the 
P3s not being sustainable.  
TABLE 8: Aim 2—Most Commonly Used Descriptors for “Failure”  
in a P3 by Stakeholder Group 
Stakeholder Group Most Commonly Used Descriptors for “Failure” in a P3 
Academic 
Researchers 
• Personalities are misaligned  
• Not enough evidence to change behaviors or policies 
Medical Clinicians 
• Lack of alignment 
• Apathy; complacency 
• Lack of implementation  
Financial Investors 
• Turbulence between teams 
• Disagreement on outcomes and resource inputs 
• Risk-taking or risk tolerance does not work  
• Technology/device/product that does not work; does not  




• Not meeting the mission or vision 
• Lack of communication 
• Partners with no experience in P3 or area of interest 
• Fail fast 
Advocacy or  
Lay Group 
Representatives 
• Not following through; bad faith 
• Duplication of work 
• Differing expectations mean end-goals are not met;  
priorities diverge 
Policymakers 
• Budget changes 
• Do not meet expectations  





CHAPTER 5: DISCUSSION 
 
To address the central question of how P3s successfully move the field of neuroscience 
forward, this study had three aims: 1) investigate factors that lead to successes and failures 
of existing P3s in neuroscience to understand the combination(s) of organizations and 
agencies that exist in the United States, 2) identify factors within existing P3s that can 
contribute to successful research and scientific advancement in the field of neuroscience, and 
3) propose federal and state-level recommendations to assist policymakers in constructing 
public policy that incentivizes and supports P3s that advance the field of neuroscience. For 
the first two aims, the literature review, questionnaires, and interviews were designed to 
construct a complete picture of the U.S. P3 environment in neuroscience through the 
triangulation of convergence. The findings from these two aims would then be used to inform 
the recommendations for policymakers (Aim 3), which will be presented in the Plan for 
Change (Chapter 6).  
Primary Factors of Consideration 
A pre-partnership process for determining stakeholder skill sets, priorities, values, and 
needs was repeatedly underscored by key informants across questionnaires and interviews as 
necessary to achieve alignment. This is particularly true in the formation of P3 due to 
preconceived notions and existing hesitations of the private sector to work with both 
academia and government. Without a precontractual assessment of each stakeholder’s 
current and future wants, needs, and capabilities, it will be nearly impossible to get all the 
key stakeholders on the same page or operating in the most efficient manner. This suggests 
that misalignment is a key factor leading to suboptimal P3 engagement.  
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In addition to the overarching need for alignment between partners, all 12 key 
informants directly noted how leadership plays a vital role in setting the tone of the 
partnership for the rest of the staff and stakeholders. The role of leaders was most frequently 
mentioned when emphasizing the need for a clear, comprehensive vision and mission. This 
suggests that leaders in P3s are seen as the visionaries who communicate big ideas and 
champion the partnership internally as well as externally; however, they are not day-to-day 
influencers or those driving P3 accountability.  
What stood out about the leadership role in science and neuroscience-specific P3s was 
the consistent reflection that those in leadership positions are not exclusively responsible for 
the P3. Instead, they are leaders within their respective organizations, agencies, or 
universities and the P3 leadership role has been added to their preexisting responsibilities. 
Thus, leadership roles within P3s appear to be consistent with governance literature 
suggesting that good decision-making and getting buy-in from others along the way is how 
leaders can keep a partnership together.56  
In contrast to leadership positions having few operational tasks, one or more people 
are needed full-time for management positions that execute the contract. This is consistent 
with literature that finds that managerial roles closely parallel project managers and research 
study coordinators as they pertain to time, cost, and quality of achieving desired outcomes.86–
88 Results from the KIIs suggest that the managerial role appears to be unrecognized or 
woefully neglected in most current science-based P3s, and this is a barrier to maintaining 
alignment between partners. The large amount of time participants spoke to the need of 
management was unexpected but signals that greater attention needs to be paid to this role, 
which should encompass responsibilities such as consistent timeline check-ins, data reports 
and standardization, communication coordination, and meeting scheduling.  
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However, it is also important to note that the frame used by participants when 
describing alignment was most often one of caution. Many health-oriented P3s begin as 
informal coalitions or loose affiliations, with limited guidance or structure.89 Therefore, 
participants consistently brought up the need for alignment in everything from broad P3 
mission and vision to narrow objectives and deadlines. Further, that alignment was distinctly 
differentiated from governance. This stands in contrast to existing literature that suggested 
governance plays a large and positive role in bringing objectives and expectations into 
alignment.43 It appears that the discrepancy in how governance impacts partner alignment has 
to do with timing. While governance can do much in the way of keeping P3s functioning, as in 
the TED Initiative, the role of leadership and management during execution is very different 
than the need for agreement before a P3’s ground rules and expectations are set.55  
The key elements of a P3 that were suggested for partnership alignment and goal 
achievement were consistent with business models for shaping organizational alignment. 
Specifically, the McKinsey 7-S Model has been widely utilized to align organizational elements 
that are both “hard” (e.g., strategy, structure, and systems) and “soft” (e.g., shared values, 
skills, style, and staff).90 The use of such a model further indicates that a P3 is most likely 
best served as a separate entity from partnering organizations’ main operations. By creating a 
distinct P3 entity, leaders facilitate an independent strategy, structure, and culture, crafting 
the P3 mission and operations apart from potentially conflicting missions and operations.  
Achieving desired results in a P3 can be quite difficult given the number of competing 
priorities, areas of expertise, and variance in risk tolerance of the partners included. This 
means that goals should be crafted and executed in a manner that either meets multiple 
needs at once or is tied to a larger purpose, allowing stakeholders to deprioritize their 
individual goals for the greater good. Thus, primary goals should be determined before the 
start of the partnership. This means that before a contract is signed, data are collected, or 
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research of any kind begins, foundational targets should be set. More nuanced, interim 
objectives can be crafted once the P3 is established.55 Further, it is a good idea to revisit 
goals on a regular basis. Within the first few months of a new P3, each stakeholder will learn 
individual and group dynamics that can shift smaller responsibilities, benchmarks, and/or 
timelines. The takeaway is that it appears there is a need for a new P3 model, one that has 
both long-term and short-term goals built in but also includes mechanisms for redefining 
those over time. Moreover, it is important to participants that all stakeholders be involved in 
setting clearly articulated, well-defined goals that are relevant to each stakeholder. While a 
couple participants were more accepting of one partner (often government) driving the P3 by 
laying out needs and limitations early on, the vast majority supported collaborative efforts in 
goal setting.  
Unexpectedly, the need to balance priorities was also presented through a number of 
synonyms and parallel phrases that referenced how those within the P3 manage their time as 
it pertains to preexisting responsibilities and new P3-oriented responsibilities. However, the 
underlying similarities by participants from both questionnaires and interviews were clear 
across stakeholder groups. Not only do organizations take on additional work by creating or 
participating in a P3, but so too do the individuals who work in the P3. Despite efficiency and 
complementary assets being the aim of a P3 (and thus lessening the long-term burden), the 
up-front costs (time, energy, money) come via sacrifice of other demands. Of those, time was 
the greatest trade-off by far for all stakeholder groups, individually and organizationally. In 
other words, there are only so many hours in a day, and when a new responsibility is added, 
other things must shift to accommodate.  
 A solution posed by study participants in neuroscience was to apply the Build versus 
Buy Decision Matrix.83 This can be translated into either making/building the infrastructure to 
fill the gap that one has internally, or outsourcing/partnering/buying the solution that will 
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mitigate the need. This type of decision-making challenge was also noted in the literature as 
more private sector companies that have merged or acquired neuroscience-based 
organizations or work find that the ROI of “buying” is greater than in-house R&D 
“building.”46,47 At its core, build versus buy decisions centered around how much 
organizations were able to sacrifice in order to make a partnership worth the effort. Without 
reasonable expectation that the input will be worth the output, many potential partners may 
rightfully conclude that the trade-off is not worth the effort. This also means that entities, 
particularly those entering into their first P3, must have a self-awareness of their wants, 
needs, capabilities, and risk tolerance for the extended period of time that most P3s require. 
Thus, any neuroscience-based P3 model should include a personal Build versus Buy 
assessment, as well as a SWOT of potential partners that contains valuation of knowledge 
resources such as intellectual property, information ownership, and scholarship recognition.91 
However, questionnaires and interviews both revealed that intellectual property 
rights, data, and media distribution contracts are an ever-increasing point of contention for 
P3s. More importantly, several respondents named intellectual property as the make-or-break 
trade-off of a contract in the field of neuroscience, as almost all new data, information, 
and/or publications are directly tied to novel works and to personal and organizational 
advancement. Showcasing successes is critical to business development, both for 
organizations and for individuals. But it can be highly complex. For example, universities are 
both major suppliers and consumers of intellectual property through grant applications, 
journal publications, and patents. But the content produced often involves several creators 
and a variety of funding sources, making ownership of ideas and ability to receive credit 
difficult.  
This suggests that legally binding agreements (especially those signed with the 
government) should be standardized as much as possible to protect partners that have a 
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personal value tied to the information. The only example specified for a best practice of 
intellectual property standardization was the CDC’s partnership division.92 Although the 
department that oversees P3s at the CDC often has a greater global and federal scope than 
many American science and neuroscience entities seek, the consistency and reliability of 
forms and processes is considered to be the best available model. Unsurprisingly, the same 
CDC partnership office was frequently cited by study participants as they spoke broadly to the 
need for both internal P3 communication (informing) and external community messaging 
(educating). The pervasive demand for communication was not effectively discussed in the 
reviewed literature.  
A call for transparency in neuroscientific research was stressed as fundamental to a 
successful P3. But, as they did with goal setting, participants spoke to the necessity for 
communication to be “multilingual”; that is, to build and maintain trust, internal and 
external messaging should be crafted to speak to the audience for which it is intended. This 
was especially true when discussing the internal day-to-day planning and operations, 
suggesting that any inadequate communication (whether it be reports, graphics, or emails and 
presentations) could result in failed progress of the P3 or flawed decision-making. 
Additionally, because of hesitations by the private sector to partner with academia and 
government, the need for trust-building is paramount. Externally, avoiding neuroscience 
jargon and employing storytelling as frequently as possible to avoid miscommunication were 
top priorities.  
While no optimal strategy for building trust internally or externally was presented, it 
was clear that trust, a necessary component of any successful business relationship, is a 
product of behavior and time. This is validated by a body of literature that shows trust is a 
necessary element of any relationship to feel safe (minimize risk) and avoid conflict.93 There 
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is further evidence that in business relationships, P3s in particular are optimized to build trust 
simply by being partnerships that are solution-oriented in nature.94 
Another factor that study participants were consistently adamant about for successful 
P3s was the need to have P3 structure, goals, and milestones set early, even before the 
contractual agreement of a P3 is signed. There was also a consistent divergent factor: 
participants remarked on the need for flexibility of structure, goals, and milestones. The 
takeaway is that in some capacity, leadership and management must be able to pivot as the 
P3 develops and internal or external shocks to the system occur. For example, in more than 
one interview, a participant described a clear set of goals that were derailed by a cut to 
funding or a shift in the disease, suggesting that the narrower a cohort or disease-specific 
area of research was, the less nimble P3 partners could be when there was a regulatory, 
funding, or technological change to the landscape.58 Several participants extended this theme 
to explain why nongovernmental entities often struggle to partner with governmental 
agencies that may be less flexible. That said, structured flexibility was most often mentioned 
in reference to internal maintenance and evaluation steps throughout the life of a P3. 
The ability to pivot requires internal and external information. The need for 
measurements was presented in a number of ways and, more importantly, crossed many other 
prevalent factors. At its most tangible and actionable reference, measurement proved to be 
essential for setting goals, reaching benchmarks or targets, staff and financial accountability, 
and standardizing protocols. It was clear that how information was collected, analyzed, 
reported, and shared was a top priority for all stakeholders. Three reviewed P3s from the 
literature also spoke to the necessity of information standardization and processes within an 
organization and between P3 partners.44,45,55 In the case of TRACK-TBI, because the DOD is a 
partner, civilian partners have to work diligently with the government to establish best 
practices and strict rules for data collection across different mediums. TRACK-TBI leadership 
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point to the need for common definitions of what is to be measured and how.44 According to 
the team, one cannot properly measure what cannot be defined and thus cannot be a 
constantly changing measure.  
The desired metrics participants most commonly illustrated were quantitative: 
descriptive/diagnostic reporting as it pertains to data collection. However, a few 
questionnaire and interviewee respondents emphasized that qualitative measurements are 
important to understand the health of the P3 and the interpersonal dynamics of the various 
partners. Moreover, that qualitative definitions and measurements should be established at 
the beginning of the P3 to lay the groundwork for what will be important about the subjective 
aspects of the P3 throughout. But SMEs were commonly recommended to take the lead in 
respective areas of measurement expertise when appropriate. The ability to lean on SMEs 
appears to be closely tied to cultural norms.  
Several interviewees provided illustrations of negative situations where culture was 
not united between partners or the culture was so unhealthy within one entity that it doomed 
the P3. In these instances, both employees and leadership were cited as potential culprits. 
This discovery was unanticipated. However, examples corroborated that because P3 staff is 
usually small in number and composed of experts, each person involved has a distinct role and 
responsibly that cannot be substituted by another employee. Thus, any avoidance of 
responsibility, hostility, or toxicity by one person can cause widespread issues with 
productivity and trust, compromising the entire partnership. Upon review, this is consistent 
with P3 research into the dual relationship between employees and leaders inside a P3.95  
Thus, finding ways to build collaboration and confidence into a P3 is a critical 
component at all levels. And, as more than one study participant highlighted, this component 
might prove especially difficult for a neuroscience-based P3 where siloed work and 
recognition is often a distinct feature of culture. Additionally, it suggests that recognition and 
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ownership of information, including publications is more foundational than previously thought 
and should be a top priority for managing and meeting P3 participation expectations. In doing 
so, non-academic potential partners must consider the uniqueness of having to address 
intellectual property that touches upon individual and joint scholarship, research, and the 
transmission and use of academic knowledge by society. 
Because individual personalities and corporate culture are so closely tied to 
momentum and sustainability of a partnership, any future policy recommendation or P3 
model should include distinct ways to reward and recognize achievements that motivate 
individuals and partnering organizations. Further support for this notion comes from a strong 
body of existing evidence concluding that personalized incentives are directly linked to 
performance and outcomes.96,97 This suggests that incentives should be created near the start 
of the P3, continuous throughout the partnership, and highly specified to the wants and needs 
of the individuals involved. 
Another important aspect of culture that came across all participants and stakeholder 
groups was the need for a P3 culture distinct from the partner organizations. Although many 
made it clear that creating a cohesive culture is easier said than done, several noted that it 
both incentivizes and advances collaboration by defining an entity that is as equally important 
as the partner organizations themselves. This distinctive P3 culture may also prove helpful in 
combating issues with ego. A further review of literature on managing personalities in P3s 
revealed that addressing ego is pervasive throughout P3 assessments and models, and this is 
not exclusive to science or neuroscience. When describing the role of ego, study participants 
spoke at length about one person putting their own desires or pride above the goals of the 
collective. Study participants often described ego-driven conflicts to demonstrate that when 
one person does not cooperate or refuses to follow protocol, the entire project and/or 
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partnership is jeopardized. Thus, special attention to culture and partner dynamics is going to 
be vital in any plan for facilitating or supporting P3s.  
Defining Success  
Aims 1 and 2 explored factors, contributions, and combinations of organizations that 
lead to “successful” P3s. A foundational part of that understanding comes from knowing how 
each stakeholder views success. Thus, all questionnaire and KII participants were explicitly 
asked to define what success in a P3 looked like to them. Interestingly, the definitions and 
examples provided for a successful P3 were much more aspirational and forward-looking than 
other answers. This was especially true for the key informants who in multiple instances 
presented their vision of success as a wish list for making the world a better place. In both 
questionnaires and in interviews, participants tended to give shorter answers when defining 
success than for any other question. It is evident that having previously participated in P3s 
provided for an easily recalled description or experience in a partnership as to whether the P3 
was a good experience or not.  
There was not convergence across stakeholder groups or within groups on a definition 
for success, but there were patterns that materialized within groups. For example, none of 
the financial investors mentioned a broader societal impact or words like communication and 
trust. This stakeholder group most frequently noted meeting objectives, reducing duplicative 
efforts, and everyone gaining from the collaboration as signs of success. This was in stark 
contrast to academics, government agency representatives, and the advocacy stakeholder 
groups. Representatives from these groups repeatedly mentioned societal impact, value to 
citizens, and real-world solutions as the overall definition of success. And yet, this is still 
different than medical clinicians and policymaker’s priorities, as they commonly referenced 
sustainability, free flow of communication and data, and clear measures for goals, budgets, 
and timelines. 
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The main takeaway from the divergent definitions of success by stakeholder groups is 
that each has expectations that must be met for them to logistically and emotionally perceive 
a P3 as worth the effort. This difference in perceptions of success was not explicitly 
mentioned in the neuroscience P3 literature, but it may explain why P3s might get suboptimal 
results when stakeholder wants and needs are not properly conveyed or understood at the 
outset. To prevent this, in addition to the recommended internal SWOT analysis and pre-P3 
partner assessments, there should be a formal business-oriented needs assessment that gets 
potential partners to openly and honestly communicate their desired outcomes. Participants 
noted that, as with any trade-off, potential partners come to the table with a range of 
outcomes that are open for negotiation. Surprisingly, a P3 needs assessment was not found in 
a literature review. However, there are assessments and gap analyses that can be taken from 
other business sectors and applied to a public-private science model.98 
One consistent theme across stakeholder groups was the desire for everyone involved 
to benefit. Phrases like “win-win” and “mutual benefit” were repeated regularly. 
Interestingly though, only the academic stakeholders noted a need for both quantitative and 
qualitative benefits. This was exemplified by academics also commenting that developing 
relationships that extended beyond the P3 was a sign of success. No one else commented on 
network or networking as an achievement. Although policymakers did convey something 
similar, these participants described success as wanting to do it again with the same people. 
Two stakeholder groups reported that smaller, iterative wins or achievements equal 
success. Yet the rationale was very different between groups. Financial investors saw 
incremental success as a means of obtaining consistent financial rewards and positive press. 
Advocacy groups suggested that smaller benchmarks were a means of learning about the 
process and recalibrating to ensure long-term success. Although different in their reasoning, 
this suggests that—much like the need for culture-based incentives to keep individuals and 
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organizations engaged and motivated—smaller rewards need to be connected to intermittent 
evaluations, in addition to long-term and sizeable goals. This can be built into a 
neuroscientific P3 model used by policymakers and scientists alike, with the CDC model as an 
example of how to embed monitoring and evaluation into the P3 processes. 
Two other factors that appeared from definitions of success were building community 
awareness, which was important for both government agencies and advocates, and cost-
savings, which was a priority for financial investors and policymakers. What these suggest is 
that the ability to reach more people and move the needle within target populations is vital 
to success for some stakeholder groups. To be happy with the outcomes, likely partners for 
those groups will want to see financial benefits and decreased or shared risk. When looking to 
transportation P3s, where the literature is strong, there is evidence that stakeholders do 
mitigate the risks that come along with innovation, including financial.4,99 This provides 
further support for the need for policy that communicates P3 demand and for a neuroscience-
based P3 model that compels potential stakeholders to openly communicate their individual 
organization’s desires and objectives.  
Defining Failure 
As with understanding what factors, contributors, and combinations of organizations 
lead to successful P3s, it is vital to explore what partners respectively consider failures and 
are thus deterrents to participating in P3s. Similar to definitions of success, definitions of 
failure strongly paralleled the defined emergent factors. Unlike definitions of success, 
however, when all 42 study participants were asked to define what a failure in a P3 looked 
like to them, they gave lengthy answers with numerous, emotional, and detailed examples of 
failure.  
For interviewees, there was some convergence around what a failure is and how it 
comes to pass, with words and descriptions of misalignment, culture, and deficiency of clear 
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goals being stated repeatedly. In fact, misalignment was specifically noted as the key to 
failure by multiple participants in all six stakeholder groups. The most notable variation was 
that academics, clinicians, and policymakers spoke most frequently to misalignment of 
culture, while government agency and advocate representatives spoke to misalignment of 
mission, goals, and priorities and financial investors spoke of misalignment in risk. This 
suggests that all stakeholders have seen failure directly result from people and organizations 
thinking they are on the same page and finding out too late that they are not. Further, 
inadequate leadership and/or misuse of management time and energy are common culprits of 
P3 demise. Specifically, for the field of neuroscience, individuals who participate in a P3 are 
often so busy with their traditional workload, they regularly overcommit what they can 
deliver to the P3 and fall short of pledged contributions and leadership responsibilities. The 
difficulty then, according to participants, is pinpointing where the miscommunications, lack 
of planning, or divergence occurred in the P3. Potential preventative measures identified 
were more precontractual communication with potential partners and more frequent 
communication points during the life of the P3. Policymakers conveyed that too few feedback 
loops lead to misalignment. This also suggests that leadership in other sectors might need to 
put greater emphasis on and time into early conversations and understanding of potential 
partners before a formal commitment is made. 
Another interesting trend in the KIIs was that several participants believed a type of 
P3 failure is external to the P3 itself. Academics, medical clinicians, and financial investors 
expressed that the ultimate failure of a science-based P3 is lack of adoption of the 
partnership’s output. For academics, this was referenced through discussing frustrations with 
lacking evidence to change behaviors. For clinicians and financial investors, examples were 
related to lack of adoption or market uptake of a product. Based on the literature review, it 
was unexpected that some individuals attributed P3 failure to external uptake, implying that 
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even if everything in the P3 went well, success or failure rests on how others engage with 
outcomes. It makes sense then, that these are the same stakeholder groups who most 
frequently voiced external communication as it relates to media and public buy-in. 
Although multiple stakeholder groups mentioned lack of trust and communication as 
influencers of failure, “ego” was again used many times, as were similar negative 
characteristics of those in a P3 who hoard information or data. Only the advocacy stakeholder 
group took this further and discussed blatant manipulation and dishonesty. This perhaps 
reflects the smaller grassroot and community organization perceptions (and familiarities) of 
being taken advantage of or being used for their community relationships. Although not an 
expected description of failure, it speaks to the unique experiences of this stakeholder group 
compared to the others. 
Another trend not anticipated was how few participants spoke of funding, even when 
prompted. It was expected that funding would be a common theme throughout P3 
questionnaires and interviews as a reason a partnership failed. But funding was only 
mentioned by the investor and clinician groups (which blamed leadership for the lack of 
funding) and policymakers (which noted that coming in over budget could be viewed as a 
failure). Surprisingly though, those funding failures were also linked to leadership and 
management failures for not properly planning the budget or not preparing for budgetary 
shifts.  
Lastly, illustrations of failure by academic and clinician interviewees often involved 
saying that there is no failure, only learning processes. There had been no previous 
expectation for this based on the literature review or the questionnaires. As for the notion 
that a P3 cannot fail if partners learn from mistakes, it is interesting to note that those who 
started their definition of failure by saying one cannot fail spent a comparable amount of 
time to their peers describing numerous failures. The primary takeaway from this anomaly is 
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that gained insights are appreciated, even when suboptimal operations or outcomes occur. 
But it is also worth considering that because many, if not most, clinicians and academics work 
in institutions where their salary and position are not tied to P3 success, perhaps they have 
fewer negative repercussions for a P3 failure.  
Broader Issues for Consideration 
 While eight factors and five subfactors were identified from the 30 questionnaires and 
12 KIIs, respectively, several anticipated topics did not appear. It is important to recognize 
that what participants did not say and topics not discussed deserve consideration, as they 
might be just as informative as the themes that were presented.84 For example, the United 
States appears to have a nationwide issue with sharing. While no one explicitly said lack of 
sharing is an issue, it appeared to be an underlying subject as participants spoke to culture, 
communication, and ego, among other factors. On many occasions, participants would say 
things such as “in an ideal world” or “if others were more willing” when they spoke about 
collaboration, particularly around data and organizational needs. This perspective might 
reflect greater specialization and silos of expertise that was instigated by university growth 
throughout the 20th century.18 However, it appears to contrast academic suggestions that 
collaboration is growing in academic circles based on the increasing number of authors and 
universities cited per publication.48  
A culture of sharing could be tied to incentives (like payment or publication). An idea 
that materialized as participants discussed present-day partnering is that no matter how 
clearly goals are defined, fundamental policy changes to enable or maintain a P3 must include 
incentives to share. Participants claimed that regulatory, financial, and political forces stood 
to be the biggest drivers of external shocks to a P3. Therefore, the primary routes of change 
could be through reducing regulatory burden or increasing financial compensation. However, 
improvements to precompetitive contracting like those in ADNI and TRACK-TBI might foster 
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greater trust and collaboration for a neuroscience P3.44,45,57 If inability to compete increases 
willingness to share, then forms and guidelines to address this should be built into a new P3 
model. 
An incentivization to share could also prove valuable in the attainment and utilization 
of neuroscientific research tools such as MRI machines and patient care. For example, 
depending on each state’s legal and legislative requirements, a university and a nearby VA 
could share equipment as part of a P3 contract, lowering purchasing and operational costs for 
both and improving data and trial output consistency obtained for mutual research purposes. 
Additionally, by reducing regulatory burden or increasing financial compensation there may 
be an opportunity for public entities to encourage the private sector to participate in basic 
neuroscience research. Due to many of the challenges mentioned, including the length of 
time it takes to see success for basic research and lack of ROI, no current models incentivize 
prioritizing, or even participating in, basic research over applied research. However, a P3 
model that decreases risk and shares cost over the long-run of basic research, may create 
enough of a motivation to shift the dynamic. Given that a common notation by participants is 
how long P3s run, a longer-than-normal partnership timeline may prove optimal for planning 
both milestones and budgetary needs. This is further supported by the common practice and 
ability of government to absorb more risk without receiving rewards than the private sector is 
traditionally comfortable doing.       
In addition to underlying issues with sharing, study participants also revealed that 
there is no standard science-focused P3 model or a common set of materials or guidelines for 
best practices. There was no consistency within or between stakeholder groups about an 
optimal way for a P3 to come together. For example, not once did any of the 42 participants 
mention the BRAIN Initiative, which was explicitly created in 2013 for such purposes. And 
when asked about it directly, participants commented that they were uncertain what it did 
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for government neuroscience efforts.41,42 Thus, participants said that potential ways for a 
neuroscience P3 to come together could include disease-specific, community-based, 
government-facilitated approaches or visionary leadership. This is consistent with 2014 survey 
findings from a community health P3, which insinuate there is no initial genesis for any health 
P3 given how distinctive each is.89 Interestingly, the participants who had the most positive 
experiences and most hopeful responses about neuroscience P3s were those whose 
experiences were grounded in a disease-specific partnership such as the ADNI discussed in the 
literature review in Chapter 2.45,59 Upon examination, the structured role that drug 
development plays in the United States is likely a driving force behind disease-specific P3s 
having more funding, traction, and more uptake in the community and/or market.21  
The role of professional organizations was expected to play a role in the development 
of P3s, given how frequently various stakeholders attend conferences, present their work, 
and join others with shared interests for networking. However, although almost every 
participant belonged to more than one professional organization, not a single one could point 
to a P3 that was formed by the network or group dynamics of their professional organizations. 
This suggests that professional organizations are used for within- but not between-specialty 
networking; they may contribute to personal growth but not cross-sector collaboration. 
However, this presents a potential opportunity for professional organizations and conference 
organizers to place a greater emphasis on cross-sector meetings, events, and interaction.  
The final two topics that presented themselves on several occasions but were not 
directly addressed at length were taxpayers and external media/communications. 
Participants spoke to communication frequently, including external buy-in from the larger 
community. The role of promotion, press, social media, and media mostly appeared as 
afterthoughts. Yet it was clear that many participants believe messaging is vitally important 
to the overall outcome. It was unclear if “media” is well understood in terms of promotion or, 
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as stated by those in the science community, if it is considered someone else’s responsibility. 
Either way, this suggests that media training or an exclusive role for external communication 
and promotion may be important for consideration. 
As for taxpayers, it appears that oftentimes when policymakers, government agencies, 
and academics referred to “the people,” they were actually trying to convey that taxpayers 
should be getting value (or have access to information) that their tax dollars paid for. This 
makes sense given that these three stakeholder groups frequently use federal and state funds 
for their P3 and non-P3 work. However, it is interesting to note that almost no one spoke 
specifically about taxes or the role of taxpayers. Two policymakers briefly mentioned that 
they represent the taxpayer stakeholder group and that when “they” are a P3 partner, as 
much data as can be made public should be. The takeaway is that few participants appear to 
consider working with government agencies as directly working with and for the American 
people. And yet for policymakers, this will inevitably be a priority, even if they have not 
spoken about it.  
Limitations  
There are several limitations to this study. First, the small sample size limits 
generalizability. Second, 23% of people approached for surveys and 33% of those approached 
for KIIs declined; to the extent that non-responders may have had different perspectives, this 
also limits generalizability in developing the survey and interview questionnaires. Third, 
despite having two persons review the interviews and questionnaires, the principal 
investigator potentially introduced bias due to her familiarity with the subject of 
neuroscience and background knowledge of the partnerships and some participants.100  
Implications and Future Direction 
The purpose of this study was to investigate factors that lead to successes and failures 
in P3s, specifically those in neuroscience. Further, the study aimed to identify factors within 
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existing P3s that can inform and contribute to the proposal of federal and state-level 
recommendations for incentivizing and supporting P3s in neuroscience. This study was 
necessary as a starting point for improving P3s in the field and being a catalyst for scientific 
advancements. 
The six stakeholder groupings were sufficiently diverse to provide a detailed picture of 
the unique drivers, expectations, hesitations, and needs based on their cohort’s expertise and 
experiences. However, within the six stakeholder groupings, only a few factors proved to be 
homogenous. This suggests that although there are distinct trends based on area of expertise, 
individuals within stakeholder groups had very different experiences based on their previous 
partnerships. This indicates that each stakeholder group needs greater exploration about 
their unique skill sets and challenges. Further, in the instances of thematic overlap (primary 
factors and subfactors), great attention must be paid to meeting those needs or integrating 
those lessons learned, as they will regularly influence P3s in science.  
The information obtained from SME questionnaires and interviews, as well as the 
limited existing literature, suggests that this primary exploration of basic definitions and 
experiences will be foundational in not only effectuating new policy language and priorities 
but also in creating a new P3 model that is built around the unique challenges and outcomes 
that novel science requires in the 21st century. This study provides a much deeper and richer 
understanding of the considerations, hesitations, and desires of those who wish to enter into 
a neuroscience partnership. 
The most encouraging and consistent feedback from study participants is that P3s are 
potentially an important model for science and the field of neuroscience. Further, there are 
no indications by any participant that P3s would be an unfavorable or less critical model than 
exists in the space today. Instead, the key takeaways are that incentives are commonly 
misaligned, many that partake in P3s are not well versed in business practices, and there are 
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currently no best practices, guidelines, or models to help overcome the actual and perceived 
barriers of partnering. 
Because federal and state policies and programs are entangled due to oversight and 
budgeting, it can be difficult for nongovernmental individuals to understand the processes 
and engage with government. Long timelines and bureaucracy are also seen as hindrances to 
many outside public policy. The findings of this study suggest that resulting disengagement is 
much more deeply entrenched in social norms than previously understood. Although no 
participants listed policy as a reason for P3 failure, many said that politics were reasons they 
hesitated to join a P3 or found them risky. Therefore, in addition to proposed policy changes 
for state and federal policymakers to consider, incentives within policies, public outreach, 
and education may be necessary first steps for nongovernmental engagement. 
However, due to the timing of this publication, it must be noted that the implications 
of the COVID-19 pandemic are yet unknown. And further, that all the information obtained 
from study participants was collected and analyzed before the declaration of a pandemic. 
With that in mind, it should be noted that both federal and state research priorities, foci, and 
funding will certainly shift due to the severity of the public health crisis. On one hand, this 
may draw attention away from the field of neuroscience. But on the other hand, knowing that 
the virus crosses the blood-brain barrier, means there is potentially a lot to be learned from 
brain-based research. Additionally, the federal government could invoke its authority and 
ownership rights over patents for inventions that have any government funding, as well as 
some instances in which private company innovations do not receive government funds. Given 
the current unknowns of the pandemic, companies receiving federal funding should prepare 
for the federal government to step in and take control of patents associated with novel 
breakthroughs; lending much credibility to the need for a more formalized P3 framework. 
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As for a new science-oriented P3 model, it appears that the CDC Strategic Partnering 
Framework (Figure 1) and the NINDS and DOD TRACK-TBI model would be good foundations for 
an updated model that reflects the distinctive needs and challenges of those in science and in 
neuroscience in particular.44,63 Specifically, special attention should be paid to pre-model 
evaluations, time allocation, communication, and business acumen. Guidelines, frameworks, 
and contractual examples likely need to be built into this new model to establish a 
standardized baseline for P3 engagement. Additionally, those engaging in the P3 should 
intentionally create an independent entity with its own charter.89  
A plan for change should not only include recommendations to assist policymakers in 
constructing policy, but it should also entail a new P3 model to be used as a guide for 
neuroscience-based partnerships. A communication plan is integral to bridging the 
misunderstandings between governmental and nongovernmental P3 partners, as well as 
garnering buy-in that will hopefully shift broader cultural challenges associated with 
willingness to share. To accomplish this, the Knowledge to Action Framework (Figure 2) is 
used to translate the information learned to application, including feedback loops for real-
time modifications.  
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CHAPTER 6: PLAN FOR CHANGE AND RECOMMENDATIONS 
 
The findings of Aims 1 and 2 of this study, along with the literature review, suggest 
P3s could play an important role in advancing neuroscience research and work. By bringing 
together and optimizing complementary people, ideas, and resources from the public and 
private sectors with a shared goal, partners can more efficiently and effectively produce 
neuroscientific advances for the public. Findings also suggest that much more is needed than 
federal and state-level policy recommendations for the uptake of P3s in science. Major 
barriers to neuroscience P3s exist within organizational culture in the United States and the 
lack of a guiding model for how to partner. Finally, there appears to be a significant gap 
between government policymakers and nongovernment stakeholders as to the incentives, 
wants, and needs for forming a partnership. 
This plan for change has been designed to explain how modified public policy, a new 
P3 model, and an effective communication strategy may improve the pursuit of P3s in 
neuroscience; this plan also has the potential to facilitate and support P3s in other scientific 
fields. The proposed plan for change is divided into three sections: 1) federal and state policy 
changes to incentivize neuroscience-based P3s, 2) the creation of a new science-based P3 
model, and 3) a communication strategy to improve public and private sector understanding 
of government P3 objectives and capabilities. The Knowledge to Action Framework was used 
as a guide for synthesizing findings, outlining public policy actions, and creating a new 
science-based P3 model. Monitoring and evaluation criteria will also be incorporated into the 
new model.  
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Recommendation 1: Federal and State Policy Changes to Incentivize and Support P3s 
  To meet real-world challenges and overcome barriers, public policy needs to more 
effectively mobilize resources and develop solutions to complex problems. This includes using 
cross-cutting sectors and policy domains. This is especially true for the field of neuroscience, 
given the impact that brain-based understanding and advancements could have on areas of 
public policy such as education, housing, justice reform, and transit. Therefore, the signals 
and policy shifts needed for greater acceptance of P3s must include legislation (including 
appropriations) and agency implementation (action and oversight). The primary areas of focus 
should be outreach efforts to enable nongovernmental people to better understand and find 
P3 resources and to incentivize P3s through decreased regulatory hurdles and/or increased 
monetary motivations. Accomplishing these objects can be done legislatively through political 
interest, will, and funding as well as through government implementation efforts and 
oversight by the regulatory agencies accountable for partners. Using legislators’ direct 
influences on crafting policy and their indirect influence on coalition-building, 
recommendations have been divided into 1) legislative actions and examples for change and 
2) implementation methods for how agencies can carry out P3 policy intention with clarity.  
Legislation 
There are several legislative avenues to promote P3s in neuroscience. Successful P3s 
require collaboration, efficiency, cost-savings, and shared risk, which may be appealing to 
policymakers and constituents alike. Given federal and state-level budget constraints, 
particularly in mid-2020 as the COVID-19 pandemic introduces a myriad of scientific and 
federal budgetary challenges, dollars spent on novel science will continue to be limited. 
Further, as dynamics shift due to changes in public health infrastructure and research 
priorities, any form of cost-savings or shared cost increases political feasibility and bipartisan 
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buy-in will be welcome. This plan for change proposes five direct actions or examples for 
policymakers to both facilitate and support neuroscience P3s.  
1. Update the Bayh-Dole Act 
The bipartisan Bayh-Dole Act, adopted by Congress in 1980, was designed to address 
issues with commercializing technology developed with federal funding. The Act permits 
institutions and grant recipients (including universities) the title to patents that stem from 
government-funded research, as well as the ability to license the rights to private sector 
partners for monetization.101 Between 1996 and 2015, the Bayh-Dole Act spurred licensing 
activity for almost $600 billion and supported an estimated 4.2 million U.S. jobs.102 
Additionally, the P3s that have come from the Act, even in limited scope, are credited with 
more than 200 new drugs and vaccines; prior to the Bayh-Dole Act, no drugs had been created 
from federally funded research.103  
One consistent and growing challenge to partnerships outside government was 
financial incentives for back-end monetization or ownership of intellectual property. Updates 
to the Bayh-Dole Act in 2018 did not adequately address this issue. Modifications to this Act, 
such as ensuring that the federal government cannot seize control of a patent if it fits 
government health needs and predetermination of licensure use could be vastly expanded to 
assist academia, private industry, and nongovernmental organizations (NGOs) with more trust 
and financial incentives. Additionally, by updating this legislation and the intellectual 
property that it protects for nongovernmental partners, many neuroscientific advancements 
in academia and private labs could be made, digitized, shared, and monetized. 
2. Use the Public-Private Partnerships for Prosperity (P4) Act as a Model 
In September 2019, the Public-Private Partnerships for Prosperity (P4) Act (H.R.4485) 
was introduced to the 116th Congress in the House of Representatives. The Act directs 
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General Services Administration to establish a pilot program of entering into P3s to conduct 
projects to acquire space for public building purposes.104 While health was not included in the 
scope of the bill, it is a legislative milestone for creating a federal P3 pilot program with a 
budget, timeframe, and goals. Further, the P4 Act establishes a potential means of reviewing 
and evaluating P3s against other government partnership models, establishing P3s as a viable 
option to meet governmental needs.  
The likelihood of this bill passing is unknown, but the proposed legislation stands to 
potentially change the procurement culture to one that is more outcome based and 
transparent. It also stands to be an ideal means of making R&D tax credits accessible to start-
up businesses for short-term federal projects. Further, because many states lack the 
technical expertise and capacity needed to execute on large projects (particularly those 
whose conclusions impact the whole of society), the establishment of such efforts has an 
important role at the federal level.105 Using this legislative language as a model, pilot 
programs can be created via health and science-based legislation at the federal level, 
garnering bipartisan support for specific projects.  
3. Utilize the Congressional Neuroscience Caucus 
The Congressional Neuroscience Caucus was created in 2010 as a bipartisan effort to 
support the field of neuroscience and raise awareness about the intrinsic role that brain 
research plays in humans and society.106 While the caucus has been responsible for 
approximately two briefings per year since that time, its outreach does not go much beyond 
AD or health-specific briefings and support of the Society for Neuroscience’s (SfN) annual 
Capitol Hill Day.107  
Given the depth and breadth of brain-related research and the public policy 
transformations that will result from learning more about environmental and contextual 
influences on brain development and change, the Congressional Neuroscience Caucus could 
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take on a much greater role. Primarily, the caucus should develop and promote more 
legislation. Secondarily, the caucus should create a congressional roadmap for sponsoring 
more briefings, hold information sessions, and draft more Congressional Record Statements to 
enhance communication. Efforts ought to also include sending caucus members to build 
alliances and partnerships across other caucuses such as housing and justice. There are 
several parallel caucuses, including those addressing antimicrobial resistance and 
vaccinations, that could be used as a prototype on how to advocate and legislate for negative 
monetary, high regulatory industries that benefit the greater good. 
4. Consolidate/Streamline Partnership Offices 
As P3s have become an increasingly effective strategy for bringing sectors together, 
federal agencies have seen a growth in the number of partnership offices and departments. 
The most commonly cited example of what people would like to see is the CDC, which has 
created a P3 division within its Office of the Director. That division initiates and manages all 
partnerships, keeping forms consistent, protocol in place, and a team of partnership experts 
to manage paperwork and minimize conflict.108 
Unfortunately, other agencies and institutes lack such coordination. For example, 
every NIH subsidiary has its own partnering office. The same is true for the Departments of 
Defense, Veterans Affairs, Health and Human Services, and many others. This leaves 
governmental and nongovernmental agencies alike dealing with unnecessary duplications of 
paperwork, inefficiencies, miscommunications, and siloed projects. The declaration of a 
pandemic in early 2020 has drawn increased attention to the lack of a streamlined process for 
partnerships and increased the desire for efficiency and consolidation. Specifically, there is 
currently no “one-stop shop” for consistent information about partnering with government. 
Experts at the CDC convey that their much-lauded partnering office has been able to uniquely 
address partnering challenges in an efficient manner because of the CDC Foundation.109 The 
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CDC Foundation is an independent nonprofit (and the sole entity created by Congress) to 
mobilize private sector and philanthropic resources to support all CDC efforts. 
Given that duplicative work and inefficacies deter partnering and contribute to the 
technical assistance gaps that exist, another federal agency could set up a P3 department to 
synchronize and oversee all the others. The Government Accountability Office (GAO) has been 
established as the coordination agency, as well as the “congressional watchdog,” for many 
other cross-sector and cross-agency initiatives.110 Further, the GAO was at the forefront of P3 
partnership projects as far back as 1989, reporting on demand and key elements for Congress 
to consider in P3s.111,112 To improve productivity and streamline work, Congress should task 
the GAO with creating a new P3 division of federal government partnering experts, freeing all 
other agencies of that responsibility and obligation. However, given that the GSA has been 
tasked with P3 pilot programs under the P4 Act, and that both legislative and executive buy-
in is necessary for success, a joint GAO/GSA effort may be an optimal alliance or partnership 
itself for this one-stop-shop. That is not to say that no other partnership divisions or offices 
should exist within specific agencies to accommodate individualized culture and expertise; 
however, duplicative efforts have proven inefficient, and a primary centralized office could 
significantly decrease paperwork, confusion, contradictory information, and wasted time.  
5. State-Level Progress 
Thirty-eight states and the District of Columbia have enacted statutes that use P3s 
(mostly transportation related), showing that states are beginning to embrace the idea of 
shared risk and resources as funding shortfalls and demand for diverse supplies increase.113,114 
One recent example is Missouri, whose governor signed legislation (Million Dollar Boondoggle 
Act of 2019) that permits state universities to use P3s for campus projects and needs. With 
that framework, a university’s medical center and research laboratories could also, in theory, 
begin to partner for needed resources. While none have been executed in health or science 
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outside of infrastructure (building hospitals) and population health demands (housing, 
transportation), legislators have opened the door. The ability to use a P3 in this manner has 
only recently been explored, but an examination of state-level P3 adoption suggests that by 
economically and politically affording state universities to partner, the demand for P3s 
increases.115 This was true for both conservative and liberal state governments, with 
conservative state leaders adopting P3s at a greater rate.  
Of further note, the 2020 Annual Meeting of Governors is slated to discuss P3s in 
transportation, water, energy, public buildings, airports, and the environment, suggesting the 
curiosity and political feasibility for P3s is ever-increasing at the state level.116 Unfortunately, 
health and science are not in the P3 discussion just yet. Due to the COVID-19 pandemic, it is 
certain that no 2020 Meeting of Governors will take place without special sessions on public 
health and science being added to the agenda. Additionally, with more time, exposure, and 
knowledge of health-related issues, health and science could be a key piece of the state-level 
conversation and action. 
Implementation 
Once policymakers have taken direct action through legislation and political channels, 
there is still the great challenge of garnering public buy-in, building trust, disseminating 
information, and creating a user-friendly means of getting P3s organized and operational. 
There is an additional need to ensure appropriate maintenance and oversight throughout the 
life of the P3, particularly if it is funded through taxpayer dollars. To accomplish this, four 
agency-level implementation, action, and oversight recommendations have been produced in 
hopes of supporting neuroscience-based P3s with currently available resources, as well as 
anticipating legislative changes like those recommended above.  
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1. One-Stop Shop 
To give P3s the best chance of delivering on policy promises, it will be important to 
streamline and simplify partnering requirements, thus lowering the barriers to entry. Due to the 
sheer volume and complexity of assessments and legally binding contracts, it has been proposed 
in this plan for change that a one-stop shop be created within the GAO (and perhaps as a 
partnership between GSA and GAO) to execute on all federal-level agency P3s. But the agency 
in charge of such a reorganization is only part of the equation. Potential partners need to also 
have a well-defined, evaluated process for meeting required steps and completing paperwork. 
The easiest way to think of the function of a centralized P3 body is that of a hub and spoke: one 
agency handles all the day-to-day paperwork, legal language, and framework of the 
government’s partnering system, while individual agencies execute on the P3 deliverables. 
However, because this one-stop shop would manage everything from pre-P3 organizational 
evaluations to intellectual property and data use agreements to evaluation and reporting 
standardization, it is necessary to have both legislative and executive branch participation, 
again pointing to a potential need for GAO to align its efforts with GSA. This one-stop shop 
additionally means that the access point to so many potential public partners is narrowed, 
which can best match complementary skills and resources to the needs of agencies. 
To create a centralized resource for P3s, the primary legal and contractual obligations 
should be crafted to be as wide ranging as possible but designed for specification. Through 
this entity, Memorandums of Understanding and Nondisclosure Agreements can be managed 
solely based on best business practices, freeing various stakeholders of that burden. Because 
neuroscience is in its infancy as a field and because of its importance to human development 
and interaction, it is probable that almost every quality trial and undertaking is an 
opportunity to learn—even at the most basic research level. Thus, nowhere is it more 
important to remove administrative burden and confusion, for the sake of progress.  
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2. Infrastructure Support From the Administrative Conference of the United States 
Agencies need a standard infrastructure for building relationships, convening cross-
sector experts, and supporting the administrative process of partnering. On a federal level, 
that has been the role of the Administrative Conference of the United States (ACUS).117 This 
independent agency is tasked with convening expert representatives from public and private 
sectors to improve policy processes and procedures. While very few in or out of government 
know ACUS exists (i.e., only one study participant had heard of it), it appears to have played 
a fundamental role in several federal regulations and the administration of federal programs 
that support partnerships that resemble P3s. Given the historical experience and purpose of 
ACUS, it could easily be utilized more often to leverage support and cross-sector 
infrastructure in government P3s.  
 In recent years, the FDA has taken steps to encourage efficiency in clinical trial and 
device research and to lower regulatory obstacles often associated with government approval. 
Two examples are the precertification pilot program for digital health and the premarket 
approval process for scientific and regulatory consent for medical devices.118,119 Both are 
required to continuously collect input from the public and to use statutory authority to work 
with the public on new health technologies. This precedence is a significant opportunity for 
the field of neuroscience, particularly noting that study participants wanted fewer regulatory 
hurdles for novel work, not only to work with the FDA but perhaps other agencies if they use 
the FDA’s pilot programs as guides for their own agencies. With the oversight of ACUS, the 
coordination, implementation, and administration of pilot P3s that decrease regulatory 
burden (like those at the FDA) could be significant for new neuroscience research. 
3. Expansion of the Small Business Innovation Research Program 
The Small Business Administration (SBA) serves as the coordinating and reporting 
agency for the Small Business Innovation Research (SBIR) program, which supports bringing 
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domestic businesses to engage in federal R&D.120,121 What makes this program so attractive for 
facilitating P3s is that its ultimate intention is to support scientific research that leads to 
commercialized products or devices. The statutory purpose of SBIR is to strengthen the role of 
scientific innovation for federally funded R&D, while a complementary technology-transfer 
system assists with the partnering to make that a reality. 
Any federal agency can participate in the SBIR program when R&D needs are not being 
met, so long as they ensure their partnering and data privacy rules meet all the SBIR 
minimums. In fact, every agency with an extramural research/R&D budget of more than 
$100,000,000 must participate in the SBIR program.122 With its storied successes and singular 
focus on small businesses, the SBIR program should continue to stand alone. However, its 
authorization expires in 2022. When it reauthorizes the program, Congress could expand SBIR 
funding and reach into non-participatory agencies. The SBIR program could serve the field of 
neuroscience well by creating a brain-based track of initiatives. Given that every agency can 
and will be impacted by neuroscientific advancements, it would be a natural extension of 
current SBIR programming and could be built into the 2021 reauthorization process.  
4. Reignite the BRAIN Initiative 
The BRAIN Initiative is a P3 created in 2013 with the goal of accelerating research to 
understand how the brain records, processes, uses, stores, and retrieves information to shed 
light on the complex links between human functions and behavior.42 Interestingly, as noted in 
the findings, the BRAIN Initiative was almost completely unknown to all participants in this 
study. This begs the question of why, outside the four primary partner institutes, the BRAIN 
Initiative has neither grown in funding or projects nor attracted new partners.123  
The answers appear to reflect both administrative changes in the past 7 years, as well 
as lack of priority within the National Science Foundation, NIH, and White House. For 
example, calls for proposals, partnership announcements, and publications are difficult to 
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find and, in some cases, dated 2014. The BRAIN Initiative has been criticized for pre-selecting 
the initial four partner institutes without any intention of opening the selection process up to 
additional candidates. Further, once those primary partners determined areas of focus, scope 
of work, and research parameters, there has been little to no outside influence, inclusion, or 
opportunities. This applies to everything from funding to public calls for proposals. Published 
research resulting from the BRAIN Initiative has continued though, albeit almost unnoticed by 
the neuroscience community.  
The BRAIN Initiative is a crucial place for greater P3 facilitation between clinical 
investigators and manufacturers. Its primary charges include to “reduce barriers to negotiating 
partnerships” and “streamline legal and administrative processes for partners,” both of which 
study participants viewed as necessary for engaging with government for P3s. As such, 
collaborative support of the BRAIN Initiative needs to be revisited, and those agencies tasked with 
executing the initiative need to be reignited. An effort to regenerate the BRAIN Initiative will 
take both agency effort and funding, but the subsequent results could be a much more robust 
facilitation and maintenance of neuroscience P3 efforts as well as breakthrough research.  
Recommendation 2: Create a Science-Based P3 Model 
A pervasive topic mentioned by all respondents was the lack of P3 modeling that lent 
itself to science as a whole and to neuroscience specifically. The CDC’s Strategic Partnering 
Conceptual Framework is a commonly used P3 model in public health; however, because this 
model is for public health in general, it is not an optimal fit for challenges faced by U.S.-
based agencies, scientists, and various other stakeholders. Thus, a new model is needed that 
reflects the process of forming and maintaining a P3 in science in the United States. This 
model must also be comprehensive in its approach and support best practices established by 
other P3s. This new model can be used by entities seeking to explore a P3 or by a government 
agency (most likely the GAO) as the framework for all science-based P3s. 
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Conceptual Framework 
The Science-Based Public-Private Partnership Conceptual Framework (Figure 4) is 
intended to be a comprehensive guide beginning before a P3 is established and working 
through long-term evaluation and reporting; it can be applied at any stage of the partnership 
process and any one side of the model can be completed by an individual organization. 
FIGURE 4: Science-Based Public-Private Partnership Conceptual Framework 
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As with the CDC model, the left side of the framework illustrates the progression of 
assessment by the instigating organization. The identical right side of the framework 
describes the same process as it should be executed by the potential partnering 
organization(s). The center column depicts the steps that need to be taken cooperatively and 
lists the criteria and definitions that need to be jointly agreed upon. This is the phase called 
“prepare.” The framework progresses top to bottom, as the P3 progresses, prompting each 
partner individually and jointly. Once preparations have been taken, the next phase is 
“procure,” where partners are selected and baseline parameters are set. Next is the 
“manage” phase, which includes both partnership building and maintenance and evaluation of 
the P3. The final stage incorporates a feedback loop, taking partners back to each previous 
stage for re-evaluation.” The reason for this is that at any given point in time, it may make 
sense for partners to complete an individual assessment or revisit the core reasons for 
establishing the P3. For convenience of understanding the primary considerations and goals of 
each phase, a supplementary Science-Based Public-Private Partnership Assessment Criteria 
document has been created (Appendix 6) that aligns with the conceptual framework. 
It is important to note that the Science-Based Public-Private Partnership Conceptual 
Framework contains elements of construction, operation, and maintenance of a P3. While this 
model does not include technical, behavioral, or cultural competency or skill-based 
programming, those are necessary for corporate change and should be considered by all 
potential partners. However, it does not include information regarding P3 financing or design, 
as those are based on the individual project and contracts. This model also implies that like 
the World Bank definition used for P3, there is shared risk and ownership of the P3 between 
the partners. Thus, merely transactional exchanges of scientific work do not qualify as a P3 
and will likely not gain value from this framework.53  
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In each phase of the framework, the plan for change includes standardized forms and 
guidelines for reference. These are integrated to aid those who are new to P3s by having 
vetted examples of the kinds of questions and contracts they should be considering. Having 
this information easily accessible also means that there are fewer barriers to partnering and 
more protections in place for partner consideration. Figure 4 shows the new framework that 
will assist those working in and around the field of neuroscience to form a P3. Each phase 
description is accompanied with high-level references and commonly accepted forms in 
scientific partnering.  
PREPARE—Organizational Assessments  
The first phase of the framework begins with a deep understanding of one’s own 
capabilities and the partnership activities that are desired for a specific impact. At the very 
earliest stage, conducting initial assessments will help determine the potential viability of 
long-term planning and set the stage for negotiation and goal setting. An organizational 
assessment should include defining individual organizations’ goals (if not already determined), 
mission, project-specific priorities, readiness of internal assets (e.g., people, time, and 
expertise), and the limitations facing the organization. It is also important to evaluate the 
leaderships that exists (or does not) and the risks that are considered acceptable.  
Once all potential partners have completed this self-evaluation and compiled 
background information, discovery meetings and conversations around potential common 
goals and priorities begin. Again, this phase includes asking the difficult questions about 
mission, vision, purpose, and level of commitment. Many of these initial joint activities call 
for trust that may be difficult to establish when potential partners are unknown, 
inexperienced in partnering, or have been unable or unwilling to share their work in the past. 
Thus, during this phase, there are a series of guidelines, assessments, and forms that can be 
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utilized individually and jointly as a means of gaining preliminary buy-in, building trust, and 
eliciting authenticity from potential partners. Several tools may be useful at this stage:  
• Strengths, Weaknesses, Opportunities, Threat Framework85 
https://store.hbr.org/product/using-the-swot-framework-in-the-healthcare-
sector/W16448 
• Build versus Buy/Make or Buy Decision Matrix124 
https://www.inc.com/yoram-solomon/a-simple-tool-for-better-make-vs-buy-
decisions.html 
• The Balanced Scorecard—Performance Measures125 
https://hbr.org/1992/01/the-balanced-scorecard-measures-that-drive-
performance-2  
• Core Competencies126  
https://www.bain.com/insights/management-tools-2011-core-competencies  
• Development of Memorandum of Understanding/Memorandum of Agreement127 
https://www.cdc.gov/partners/pdf/policy597.pdf 
• Nondisclosure Agreements128 
https://www.cdc.gov/os/technology/techtransfer/researchers/formsagreements/i
ndex.htm 
• Research Collaboration Agreements129 
https://www.ott.nih.gov/resources  
PROCURE—Partner Selection 
As individual organizations come together and begin to address whether goals and 
priorities are sufficiently aligned to consider partnership, revisiting internal capabilities and 
external options is a continual process. However, at the partnership selection phase, more 
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pronounced commitments and formalized drafts of consensus should become clear. By having 
put nondisclosure agreements and memorandums of understanding in place, as well as a deep 
understanding of where each potential partner stands in real time, open conversations can be 
had about how resources (including but not limited to expertise, money, time, staff, skills, 
network, leadership) might be used. 
If it is determined there are shared goals and complementary resources/assets, some 
levels of participation can begin to take shape under a partnership agreement. For example, 
potential partners should consider if the project is best established at the national, state, or 
local level or whether one partner should have more advisory or directive roles over another 
based on funding or agency parameters. This is also the time to have candid conversations 
about what each partner views as success and failure of a P3 in the space and about how the 
P3 might be governed. Listening to and acknowledging individual partner objectives is vital at 
this phase, as is discussing who will have ownership, usage, and sharing rights to information 
and data. At this time, there are opportunities for new information to present itself, COI to 
arise, power dynamics to come to the surface, and cultural barriers to hinder the partnering 
process. To offset this, a number of resources can be used to assess risk, define success, and 
lay out data agreements.  
• Conflict of Interest (COI)/Conflict of Commitment130  
https://ura.uchicago.edu/page/conflict-interest-conflict-commitment-coi-coc  
• Collaborative Research Agreement131 
https://braininitiative.nih.gov/sites/default/files/pdfs/brain_ppp_cra_9172015_508c.pdf 
• Confidential Disclosure Agreement132 
https://braininitiative.nih.gov/sites/default/files/pdfs/brain_ppp_cda_091715_508c.pdf  
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• Wilder Collaboration Inventory133 
http://www.brauchtworks.com/yahoo_site_admin/assets/docs/Wilder_Collaborati
on_Factors_Inventory_and_Interpretation_Guide_180218.48132945.pdf 
• Fiscal Risk Assessment Model134  
https://www.worldbank.org/en/topic/publicprivatepartnerships/brief/ppp-
tools#T2 




MANAGE—Partnership Building  
Once the exploratory phases of the framework are complete and a P3 begins to move 
forward, a host of new considerations must be addressed. On an individual organization level, 
these include allocation of staff and resources that will be used for the P3, as well as how 
roles within the organization will change (including new hires) as a result of P3 commitments. 
If a potential partner has elected not to move forward, this is also the time to engage those 
organizations for any in-kind contributions or expertise that might be beneficial in a non-P3 
capacity. End-users are also an important stakeholder at this phase. In neuroscience, the 
ultimate user or patient population is often not engaged early, and key objectives or data 
points are missed without that perspective. 
Collectively, during the partnership building phase, roles and responsibilities begin to 
take shape and both short- and long-term planning come together. It is important for partners 
to recognize that most P3s have a long timeframe, and planning must accommodate roadmaps 
that have future unknowns in planning and expectations. At this point, commitment letters 
should be signed and formal contracts should be near completion. However, based on study 
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participant results, this is the most difficult phase of the P3, as there are a lot of moving 
parts. Specifically, as roles and responsibilities are defined, so too are the objectives, 
outcomes of interest, and benchmarks along the way. What this means is that for each P3, 
the order in which steps are finalized will vary with the P3—each locking in a unique aspect of 
the overall partnership. For example, a disease-specific P3 may have a very clear division of 
labor and chain of command, but no definitive timeline, budget, or communication strategy. 
On the other hand, a government-funded P3 may have a non-negotiable budget and timeline, 
but the specific partners and roadmap to meet the regulatory requirements are left to the P3 
itself. 
The ultimate takeaway of this phase is that it is constantly evolving. Additionally, the 
core mission and commitments should be front and center at all times, building all other 
characteristics on those. The most important aspects of defining roles include establishing 
leadership positions, selecting management, agreeing on division of labor, and setting 
expectations, as these will determine both the culture and the accountability of the P3. 
Other considerations in this phase are establishing clear timelines, internal and external 
communication plans, and a conflict resolution strategy.  
As details come together, long-term objectives and shorter-term milestones (including 
reward mechanisms) will be clarified, clearing the way for a plan for holding stakeholders 
accountable and ensuring that the P3 is healthy, moving in the right direction, and on course 
at all times to deliver on the mission. To overcome the difficult challenges and feel secure 
that the P3 is setting itself up for success, a series of strategies may be employed for bringing 
alignment and clarity to stakeholders. These include comparing key performance indicators 
(KPIs), setting SMART goals, and completing a roles and responsibilities matrix.  
• SMART Goals136  
https://www.mindtools.com/pages/article/smart-goals.htm 
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• Key Performance Indicators137 
https://www.pwc.com/gx/en/audit-services/corporate-
reporting/assets/pdfs/uk_kpi_guide.pdf 
• Responsibility Assignment Matrix Chart138 
https://thedigitalprojectmanager.com/raci-chart-made-simple/ 
MANAGE—Maintenance and Evaluation  
Once a P3 is officially underway, maintenance and evaluation efforts should begin 
immediately. Accountability and progress reports are vital in the early days of a P3 to ensure 
short-term goals are on target and to identify any unexpected risks or challenges to the plan 
or execution. This process should be both formal and informal. Assessing predetermined 
measurable outcomes can often be done by reviewing data. If goals are not being met or the 
culture is not healthy, different evaluation methods need to be used. This is a primary reason 
a feedback loop has been integrated into all four phases of the framework. These findings 
clearly suggest that the unexpected has to be expected in the field of neuroscience. Thus, 
both maintaining the partnership and evaluating the partnership are exceptionally important 
activities that must simultaneously occur, as they are intricately linked to one another. 
Subsequently, expectations and plans need to be revisited on a regular basis and altered to 
accommodate the state of the real world. 






• Monitoring Indicators141  
https://www.thecompassforsbc.org/how-to-guides/how-develop-monitoring-
indicators 




Recommendation 3: Communication Strategy  
Recommendations 1 and 2 lay out public policy and framework changes that can 
incentivize and support the creation of P3s in neuroscience. However, both recommendations 
highlight the need for greater communication, both in quantity and quality. Recommendation 
1 suggests the need for policymakers to improve communication style and increase the 
frequency of communication with potential nongovernmental partners. Policymakers could 
also increase communication between themselves. The Congressional Neuroscience Caucus is 
an example of an intergovernmental opportunity for more interaction with other committees 
and legislators. Recommendation 3 indicates the need for communication planning as both an 
external outreach strategy for relationship building in the community and an internal strategy 
as a means of keeping all internal stakeholders informed and on the same page. 
Because interactions among policymakers are highly dependent on relationships and 
authority, there may not be many opportunities to change communication frequency or 
strategy between policymakers. The same can be said for interactions among P3 partners. 
While P3 partnerships have more flexibility than federal or state legislators in how they 
interact with peers, P3 reporting and corresponding standards often dictate when and how 
stakeholders communicate. For those reasons, the most impactful communication changes for 
improving P3s will come from how policymakers communicate with nongovernmental 
potential partners and how P3s communicate with the broader community, end-users, or 
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target audiences. Thus, this plan for change incorporates two communication strategies, with 
examples: 1) messaging to explain why neuroscientific advancements are key to public policy 
and as such, including what P3 opportunities are available in relevant agencies, and 2) 
storytelling strategies and advocacy and community groups to garner buy-in from target 
populations. 
Policy Outreach 
 To execute an effective communication strategy that both builds and sustains 
political and popular support, policymakers must first convince nongovernmental public and 
private sectors that government can be trusted and understands the role that neuroscience 
will play in the future of policymaking.143 Assuming a GAO hub-and-spoke model for P3s in the 
federal government (Recommendation 1) and a similar one-stop shop for partnering in each 
state, general communication about neuroscience P3 opportunities should come from the 
GAO. However, language about opportunity for impact should be crafted by individual 
agencies, lending specifics such as why and how housing policy, for example, will be directly 
impacted by brain-based research and advancements. P3 communications that include both 
the overarching partnership topic and logistics or agency-specific intent stand to improve 
governmental reach by 1) having more routes of dissemination into the population at large 
through interest groups and 2) building trust about governmental intentions and operations 
for potential partners. 
To accomplish this, an effective policymaker communication strategy should include 
six key elements according to the WHO’s Strategic Communication Framework; that is, 
communication should be 1) accessible, 2) actionable, 3) credible, 4) relevant, 5) timely, and 
6) understandable (Figure 5).144 This framework was chosen based on its application to health 
and science-based considerations for trust-building and time-sensitive communication efforts 
with the public. While the stakeholder groups listed are not a one-to-one match for U.S.-
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based neuroscience P3s, the six key elements are highly applicable to the challenges faced by 
policymakers needing to communicate with nongovernmental potential partners. 
FIGURE 5: World Health Organization Strategic Communication Framework 
 
 
Accessible: Communication between policymakers and those in neuroscience starts 
with understanding 1) how the audience receives governmental science information and 2) 
the cultural hesitation to partner with the government. Thus, the communication must 
provide examples of why brain-based work is necessary and how the government can be an 
asset. Mass media is likely not a means of accessible communication; rather, the SfN website, 
respected journals and publications, presentations, and government agency websites such as 
SBIR could be effective channels.  
Actionable: The communication need is for NGOs to partner with the government. As 
such, raising awareness must be accompanied with easy-to-use ways of interacting with the 
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government. This might include calls to action that direct people to the GAO website or to an 
agency list of immediate items for solicitation. Yet action will need reinforcement, such as 
government-facilitated follow-up or forms to fill out.  
Credible: Building trust means demonstrating competence. For government agencies 
looking for partners, this again means exhibiting that the agency understands the scope of the 
issue and the unique, important role that the field of neuroscience can play in a solution. It 
also includes showing respect and being open to nongovernmental partner needs such as 
autonomy and IP, as well as being transparent from the outset.  
Relevant: Tying personal experiences into a message strengthens buy-in that the 
audience is being communicated with directly. When looking for P3 partners, it would best 
serve the government to be as clear as possible about partner needs and specific parameters. 
Tailoring each message can go a long way in keeping the potential project and the potential 
partners focused.  
Timely: Calls for partnership are often the result of an immediate neuroscientific 
need. However, the message needs to be delivered with enough time for potential partners to 
process the message. This can best be done through a series of strategies ranging from a one-
page call-to-action to social media blasts to requests for partners through a formal GAO 
process. Leveraging awareness days and current hot topics can also be a strategy for getting 
attention to P3 needs tied to neuroscience-based issues.  
Understandable: Any governmental message must clearly state the problem and the 
action a potential partner can take. By using simple language, familiar words or jargon, and 
bullet points or highlighting, potential partners can quickly and easily garner the information 
they need to make an informed decision. This element is really about meeting the reader 
where they are and building confidence that easy action can be taken.  
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Given that P3s lend themselves to attractive language (see Recommendation 1), 
outreach from public policymakers to the general public has an inherent advantage in 
appealing to a wide variety of potential partners. Maximizing impact, risk-sharing, 
collaboration, and all the other words and phrases that symbolize positive relationships can 
be displayed in simple fact sheets and impact statements. Using the WHO framework, fact 
sheets are one way to begin introducing the public to evidence-based information on the 
positive effects a P3 can have in neuroscience.  
Until future calls to action are issued, policymaker outreach must explain why the 
government wishes to initiate P3s. The Public-Private Partnership—Policy Planning and 
Implementation Fact Sheet (Appendix 7) was created as an example to detail primary reasons 
for, and common elements of, science-based P3s. This one-pager was crafted as though it is 
from the GAO, but it can also be adapted for state-based P3s. The fact sheet is meant as a 
starting point for external communication and solicitation of P3s. A secondary fact sheet, 
Considerations and Knowledge—Partnering With the Government (Appendix 8), was also 
created as an example to help highlight federal government assets and responsibilities in a 
P3. A document such as this one could be essential in resolving potential partner questions 
and alleviating concerns.  
Partnership Outreach 
As with policymaker outreach to potential partners, the WHO framework can serve as 
a guide for how P3s can build a communication strategy that garners buy-in from the general 
public and from the target audience the P3 is trying to help. This challenge can be great due 
to deeply held cultural beliefs and experiences with health care. Like policymaker outreach, 
the framework serves as a basis for maximizing impact in the general population. The 
stakeholder groups are not one-to-one comparators, but the key elements of a communication 
strategy are. However, a key difference in the execution of the WHO framework within P3s is 
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the potential need for leadership-induced transformations to achieve optimal outcomes. 
Given that a communication with the public has been a consistent hinderance in previous P3s, 
both leadership and employees need to identify and dedicate themselves to designing new 
methods of consistent communication. And further, recognize that this may include a need 
for executive coaching to re-design how communication is integrated into P3 activities.    
Accessible: Communication between a neuroscience P3 and its target audience must 
provide examples of how the work can directly improve the lives of the community. In this 
instance, mass media is a potentially powerful communication channel. By using social media, 
neuroscience listservs, print materials, news releases, and disease-specific or interest group 
channels, the target audience will get communication directly from affiliated and trusted 
sources. Transparency is also imperative in a P3’s communication with the public. This is less 
of an issue when data and information are open source but can go a long way in giving people 
access to the information that is important to them.  
Actionable: The communication need is for P3s to gain a response from a specific 
community. This could be joining a study, learning more, or buying a product. As such, raising 
awareness must be accompanied with easy ways of interacting with the P3 and the partners. 
This might include calls to action that direct people to share their story or attend an event. In 
most P3 instances, action will also need to be followed up to reinforce the idea that the P3 is 
necessary and doing its job responsibly. What makes actionable items unique in this scenario 
is that the community is a stakeholder; as such, their actions are a necessary part of the P3.  
Credible: Building trust means demonstrating competence and demonstrating care for 
the target audience. For neuroscience P3s, this means exhibiting that partners have the best 
interest of the community in mind and they are part of the solution. It also includes showing 
respect and being transparent from the outset. P3s can often rely on the experts and voices 
of authority within the P3 to build credibility based on their unique knowledge and skills.  
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Relevant: Storytelling and personal experiences strengthen buy-in and elicit feelings of 
trust. Tailoring messages to speak directly to distinct audiences and populations can help 
those who may not otherwise know how relevant brain-based work is to them become 
advocates themselves. Using common diseases such as AD can evoke empathy from many 
individuals in many communities.  
Timely: Whether the result of a movement or an uptick in the number of Americans 
affected by an issue, brain-based issues often have a short shelf life in the public eye. 
Therefore, using timely topics or events to draw attention to P3 concentrations that are 
directly or indirectly linked to those topics or events can draw larger audiences. Messaging 
must also speak to people where they are in their lives. For example, as people age, 
materials and messaging about brain degeneration are timelier than information about 
childhood development.  
Understandable: Communication can undoubtedly get lost if the recipient is not 
familiar with what is being presented to them or does not know what is being asked of them. 
As with other communication strategies, using simple language, familiar words, images, and 
stories can get relevant information to those who need it to make an informed decision. As 
before, this element is really about meeting the audience where they are and building 
confidence that the P3 is working for the greater good. 
A few of the ways P3s can gain external attention and support is through storytelling 
and media. Storytelling uses characters and contextual clues to persuade the audience of 
something. Given that every aspect of neuroscience impacts human behavior, relationships, 
health, and society, there is no shortage of stories to tell. As P3s come together and think 
about the impact they want to have, crafting rich stories and telling those to the public will 
be vital for long-term trust and support. Storytelling will ultimately influence whether the 
target population embraces the behavior change, information, or product that is a result of 
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the P3. Further, media and social media should not be overlooked. The lay community has 
embraced mediums ranging from videos to tweets for accessing information and signals about 
the world around them. These are valuable channels for putting P3 information in front of 
external stakeholders and securing buy-in.  
Plan for Change Communication Strategy 
The principal investigator has working relationships with those in the partnership 
office of the GAO, CDC, SBIR, and Congressional Brain Caucus. Thus, in addition to the 
detailed strategies for Recommendation 3, the findings of this study will be shared with 
members of those agencies and organizations, along with requests to meet. Through 
subsequent exploratory conversations, the principal investigator will begin to address the 
parts of Recommendation 1 that are politically feasible under the current and/or next 
administration.  
The high-level findings and themes of this study will also be included in a book 
proposal in late 2020. Study results suggest that the need for a new science-based P3 model is 
essential for moving science partnerships forward. Based on Recommendation 2, that new 
model will become a stand-alone book that details the stages of partnering and provides 
resources (included in Recommendation 2) for those in the neuroscience field who wish to 
embark on a P3. 
Recommendations 1 through 3 are designed to work in parallel to shift the cultural and 
operational proclivity to join a P3. These additional extensions of the recommendations will 
hopefully further that mission in several ways. This includes advancing policymakers’ 
understanding and advocacy for P3s, improving neuroscience-based organizations’ willingness 
to and ease of partnering, and providing universal education and communication about the 
role P3s can play in furthering neuroscientific advancements.  
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APPENDIX 1: ADDITIONAL KEY WORDS AND SEARCH TERMINOLOGY 
 
The following additional key words and search terminology were substituted in 
attaining background literature for the relationship between other areas of science policy  
and P3. 
Concept Key Word(s) and Search Terminology 
Public Goods “shared resources” OR “shared good” OR 
“disparities” OR “parity” OR “public payment” 
Health Care “access” OR “quality” OR “health as a right” OR 
“health payment” OR “public health” 
Private Capital Innovation “private capital” OR “private pay” 
Science Policy “science policy” OR “research policy” OR 
“science legislation” “state science policy” OR 
“federal science policy”  
Brain Injury Policy  “brain injury policy” OR “traumatic brain injury 
legislation” OR “concussion legislation” OR 




APPENDIX 2: PRISMA DIAGRAM  
 
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
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APPENDIX 3: ONLINE QUESTIONNAIRE GUIDE 
 
INTRODUCTION 
The purpose of this survey is to learn how you, as an expert, think about the future of public-
private partnerships (P3s), and their ability to move science forward—particularly the field of 
neuroscience. Specifically, I am interested in learning more about how collaboration of 
various sectors influences the ability to produce research ideas, secure research funding, and 
facilitate getting new research, devices, or best practices to the general public. To do that, I 
want to understand the social environment, organizational environment, funding mechanisms, 
and policies related to P3s in the health care space. 
The questionnaire contains 15 questions and should take less than 30 minutes to complete.  
Your responses will be completely confidential. As this is an electronic survey, the IP address 
from which you are responding will not be tracked, and no identifying information from you is 
necessary for participation. However, for initial contact purposes your name and email 
address have been provided to me.  
Any information that you provide will be kept anonymous and only presented or written about 
grouped with other interviews, as a high-level summary or arranged into general themes. For 
purposes of this dissertation, I am only interested in how academic settings, private 
organizations, government agencies, VCs, and policymakers think about P3s and the future of 
neuroscience, and how they make decisions.  
Your completion of this survey is voluntary. You are free to not answer any question or to stop 
participating at any time.  
If you have any questions about the research or questionnaire, please contact Nicole Fisher 
immediately at bnfender@email.unc.edu or +1-773-910-1098.  
PERSONAL & ORGANIZATIONAL BACKGROUND 
We are going to start with some introductory questions to better understand the history of 
your field and how organizations and thought leaders make decisions. To do that, we’d like to 
know more about your organizational structure and your personal experiences with 
collaboration and partnering as it pertains to health and science. 
In this questionnaire, we will use the World Bank’s definition of “public-private partnership”: 
a contract between a private party and a government or public entity, for providing a public 
asset or service, in which the private party bears significant risk and management 
responsibility, and remuneration is linked to performance. 
1. How would you best describe your organization/employer and your role within that 
organization as a decision-maker?  
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Organization Sector and Description (public/private): 
_________________________________________________________________________________
_________________________________________________________________________________ 
Your Role in Decision-Making: 
_________________________________________________________________________________ 
2. Can you walk me through your experience(s) working within public-private partnerships? 







3. Do you belong to any professional organizations (i.e., Society for Neuroscience)? If so, how 








KNOWLEDGE & EXPERIENCE IN PUBLIC-PRIVATE PARTNERSHIPS  
The next few questions pertain to how you (or your organization) assess your need for a 
partnership, and your processes for partnership selection, execution, and evaluation. Feel 
free to share examples. 
4. From your perspective, what are the motivations of partnering with another entity? And 









5. When you think of “success” in a partnership, what goes through your mind? Try to think 







6. Based on your perspective, what are the greatest challenges, risks, or hesitations 







7. When you think of “failure” in a partnership, what goes through your mind? Share with us 







STRUCTURE & GOVERNANCE IN PUBLIC-PRIVATE PARTNERSHIPS  
Next, the questions below aim to draw upon your experiences and insights into the structure, 
operations, and culture of public-private partnerships. Specifically, to meet health-related 
challenges we want you to think about what responsibilities, direction, and management are 
necessary for stakeholders to come—and stay—together.  
8. Share with us what you believe are the best ways for partnerships to come together 
(community-based, government-facilitated, disease-specific, etc.), and if there is a structure 
















10. From your experience, what external forces (political, financial, regulatory, etc.) have 







11. When thinking about potential goals for a partnership, what do you see as the priorities 
for establishing outcomes, output, and/or benchmarks? Think about those that are needed 







DATA & OUTCOMES OF PUBLIC-PRIVATE PARTNERSHIPS  
Lastly, we are interested in performance and outputs. Specifically, to better understand the 
relationship between data collection, evaluation, and sharing—within your organization and 
between partnering organizations.  
12. Tell us about data collection, measurement, and assessment. Particularly, when should 

















14. When thinking about what matters to a diverse set of stakeholders, what do you see as 







15. What kinds of information, metrics, and/or outcomes should be shared with internal and 





















APPENDIX 5: KEY INFORMANT INTERVIEW GUIDE 
 
Introduction 
The purpose of this survey is to learn how you, as an expert, think about the future of public-
private partnerships (P3s), and their ability to move science forward—particularly the field of 
neuroscience. Specifically, I am interested in learning more about how collaboration of 
various sectors influences the ability to produce research ideas, secure research funding, and 
facilitate getting new research, devices, or best practices to the general public. To do that, I 
want to understand the social environment, organizational environment, funding mechanisms, 
and policies related to P3s in the health care space. 
This interview contains 12 questions and should take less than 60 minutes to complete. 
Your responses will be completely confidential. No identifying information from you is 
necessary for participation. However, for initial contact purposes your name and email 
address were provided to me. Going forward, any information that you provide will be kept 
anonymous and only presented or written about grouped with other interviews, as a high-
level summary or arranged into general themes. Additionally, an audio recording of this 
interview will be created with your permission for subsequent transcription and analysis.  
For purposes of this dissertation, I am only interested in how academic settings, private 
organizations, government agencies, VCs, and policymakers think about P3s and the future of 
neuroscience, and how they make decisions.  
Your answering questions for this interview is voluntary. You are free to not answer any 
question or to stop participating at any time. Do I have your permission to proceed with the 
interview and begin recording?  
We are going to start with some introductory questions to better understand the history of 
your field and how organizations and thought leaders make decisions. To do that, I’d like to 
know more about your organizational structure and your personal experiences with 
collaboration and partnering as it pertains to health and science. 
In this interview I will use the World Bank’s definition of “public-private partnership”: a 
contract between a private party and a government or public entity, for providing 
a public asset or service, in which the private party bears significant risk and management 
responsibility, and remuneration is linked to performance. 
 
1. How would you best describe your organization or employer (public/private), and your 







The nsext few questions pertain to how you (or your organization) assess your need for a 
partnership, and your processes for partnership selection, execution, and evaluation. Feel 
free to share examples. 
 
2. From your perspective, what are the motivations of partnering with another entity? And, 










3. When you think of “success” in a partnership, what goes through your mind? Try to think 







4. Based on your perspective, what are the greatest challenges, risks, trade-offs, or 









5. When you think of “failure” in a partnership, what goes through your mind? Share with me 









Next, I want to draw upon your experiences and insights into the structure, operations, 
and culture of public-private partnerships. Specifically, to meet health-related challenges 
I want you to think about what responsibilities, direction, and management are necessary 
for stakeholders to come—and stay—together.  
 
6. Share with me what you believe are the best ways for partnerships to come together 
(community-based, government-facilitated, disease-specific, etc.), and if there is a 
















8. From your experience, what external forces (political, financial, regulatory, etc.) have 









9. When thinking about potential goals for a partnership, what do you see as the priorities 
for establishing outcomes, output, and/or benchmarks? Think about those that are needed 









For the last few questions, I’m interested in performance and outputs. Specifically, to 
better understand the relationship between data collection, evaluation, and sharing— 
within your organization and between partnering organizations.  
 
10. Tell me about data collection, measurement, and assessment. Particularly, when should 
data protocol, methodology, and expectations be set? And by whom? And further, are 


















12. What kinds of information, metrics, and/or outcomes should be shared with internal and 










APPENDIX 6: SCIENCE-BASED PUBLIC-PRIVATE PARTNERSHIP ASSESSMENT CRITERIA 
 
Organizational Assessment  
• Know your organizational mission, vision, and purpose  
• Know your personal/organizational goals  
• Determine the organizational and project-specific priorities and gaps 
• Assess your organizational strengths, weaknesses, opportunities, and threats for 
partnering  
• Determine readiness to partner, in terms of staff, resources, time, skill, and expertise  
• Assess your organizational leadership  
• Identify key individuals within your organization to participate/contribute  
• Know your organizational limitations  
 
Partner Selection  
• Determine whether you have a “shared” vision 
o If not, do you each have separate goals that would be individually furthered by 
the partnership?  
• Revisit your previous history, if any, with the other organization(s)  
• Draft and come to consensus about a mutual mission statement  
• Articulate a common project/task/reason for creating a P3  
• Determine the types of resources that each group brings  
• Determine what you can offer the other organization  
• Assess whether the other group has skills, resources, funding, time, expertise, 
credibility, name recognition, or advocacy capabilities that you need/want?  
• Determine the mutual benefits (more than transactional) 
• Agree upon the level of commitment of each partner 
• Agree upon the level and type of partnership (formal, informal, one-time, long-term)  
• Re-confirm that there is mutual respect and trust between the partners  
• Confirm that there is no conflict of interest (within or between organizations)  
• Identify any risks or legal issues to be addressed  
• Confirm that the P3 represents an appropriate cross-section of stakeholders  
• Confirm that the P3 has a unique purpose that cannot be met by any one individual 
organization  
 
Partnership Building  
• Agree upon what a success looks like for each stakeholder 
• Agree upon division of labor and workload distribution  
• Agree upon a system of accountability  
• Decide on means/frequency of communication 
• Plan for coalition-building (within and outside the P3)  
• Establish a time frame for completion of the project and/or for the P3 itself 
• Decide on a process for conflict resolution  
• Define long-term goals and objectives  
120 
• Define short-term and intermediate goals and objectives, and the accompanying 
rewards or incentives that accompany those milestones 
• Define measurable indicators for each objective  
• Describe any intended products or deliverables  
• Determine the frequency of reporting on the project  
• Determine the process for adding/admitting new partner(s)  
 
Maintenance and Evaluation 
• Revisit short-term, intermediate, and long-term goals frequently  
• Revisit accountability often  
• Revisit measurable outcomes  
• Revisit expectations frequently  
• Revisit collective and individual missions. Have they changed? If so, how does it affect 
the partnership? How will you adapt? 
• If these goals are not being met, do you need to re-assess the outcomes, priorities, 
and division of labor between groups?  
• Follow up on progress reports as necessary  
• Monitor any conflict and resolve issues as they arise  
• Assess the structure of the partnership. Is a more or less formal process needed? Do 
you need to re-establish the formality of the process?  
• Promote flexibility to establish/sustain/change an existing working framework  
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